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A B S T R A C T
Background
Serum procalcitonin (PCT) evaluation has been proposed for early diagnosis and accurate staging and to guide decisions regarding
patients with sepsis, severe sepsis and septic shock, with possible reduction in mortality.
Objectives
To assess the effectiveness and safety of serum PCT evaluation for reducing mortality and duration of antimicrobial therapy in adults
with sepsis, severe sepsis or septic shock.
Search methods
We searched the Central Register of Controlled Trials (CENTRAL; 2015, Issue 7); MEDLINE (1950 to July 2015); Embase (Ovid
SP, 1980 to July 2015); Latin American Caribbean Health Sciences Literature (LILACS via BIREME, 1982 to July 2015); and the
Cumulative Index to Nursing and Allied Health Literature (CINAHL; EBSCO host, 1982 to July 2015), and trial registers (ISRCTN
registry, ClinicalTrials.gov and CenterWatch, to July 2015). We reran the search in October 2016. We added three studies of interest
to a list of ‘Studies awaiting classification’ and will incorporate these into formal review findings during the review update.
Selection criteria
We included only randomized controlled trials (RCTs) testing PCT-guided decisions in at least one of the comparison arms for adults
(≥ 18 years old) with sepsis, severe sepsis or septic shock, according to international definitions and irrespective of the setting.
Data collection and analysis
Two review authors extracted study data and assessed the methodological quality of included studies. We conducted meta-analysis with
random-effects models for the following primary outcomes: mortality and time spent receiving antimicrobial therapy in hospital and
in the intensive care unit (ICU), as well as time spent on mechanical ventilation and change in antimicrobial regimen from a broad to
a narrower spectrum.
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Main results
We included 10 trials with 1215 participants. Low-quality evidence showed no significant differences in mortality at longest follow-up
(risk ratio (RR) 0.81, 95% confidence interval (CI) 0.65 to 1.01; I2 = 10%; 10 trials; N = 1156), at 28 days (RR 0.89, 95% CI 0.61 to
1.31; I2 = 0%; four trials; N = 316), at ICU discharge (RR 1.03, 95% CI 0.50 to 2.11; I2 = 49%; three trials; N = 506) and at hospital
discharge (RR 0.98, 95% CI 0.75 to 1.27; I2 = 0%; seven trials; N = 805; moderate-quality evidence). However, mean time receiving
antimicrobial therapy in the intervention groups was -1.28 days (95% CI to -1.95 to -0.61; I2 = 86%; four trials; N = 313; very low-
quality evidence). No primary study has analysed the change in antimicrobial regimen from a broad to a narrower spectrum.
Authors’ conclusions
Up-to-date evidence of very low to moderate quality, with insufficient sample power per outcome, does not clearly support the use of
procalcitonin-guided antimicrobial therapy to minimize mortality, mechanical ventilation, clinical severity, reinfection or duration of
antimicrobial therapy of patients with septic conditions.
P L A I N L A N G U A G E S U M M A R Y
Procalcitonin evaluation for reducing mortality in adults with sepsis
Review question
Is procalcitonin evaluation effective in reducing mortality and time receiving antimicrobial therapy in adults with sepsis?
Background
Sepsis is defined as confirmed or suspected infection associated with a systemic inflammatory response syndrome (SIRS). This condition
can evolve to an acute organ dysfunction, known as ’severe sepsis’; or to persistent hypotension, even after adequate fluid replacement,
known as ’septic shock’. Procalcitonin (PCT) is a biological indicator in the blood that has been found to increase during blood infection.
We wanted to assess whether evaluation of PCT can reduce mortality and time receiving antimicrobial therapy in adults with blood
infection. To this end, we compared PCT versus nothing, versus standard care (only usual clinical judgement) and versus other blood
chemical indicators. Nowadays, other chemical indicators include C-reactive protein (CRP), interleukins and neopterin.
Study characteristics
The evidence is current to July 2015. However, we reran the search in October 2016 and will incorporate the three studies of interest
when we update the review. For this version, we included 10 studies in this review. These studies were carried out in Australia,
Brazil, China, Czech Republic, France, Germany, Indonesia and Switzerland. Researchers evaluated participants from academic and
non-academic surgical, general and trauma intensive care units (ICUs) and emergency departments. All studies analysed adults with
confirmed or presumed blood infection. Comparisons were most commonly based on ‘standard care’, but one trial used CRP-guided
antibiotic therapy. In six trials, study authors had worked as consultants for, and/or received payments from, companies involved in
the procalcitonin analysis.
Key results
Results showed no significant differences in mortality at longest follow-up (124/573; 21.6% versus 152/583; 26.1%), at 28 days (37/
160; 23.1% versus 39/156; 25%), at ICU discharge (28/247; 11.3% versus 25/259; 9.6%) or at hospital discharge (82/398; 20.6%
versus 81/407; 19.9%), respectively, for PCT and non-PCT groups. Also, researchers found no differences in mechanical ventilation,
clinical severity, reinfection or duration of antimicrobial therapy. No study provided information about participants for whom the
antimicrobial regimen was changed from a broad to a narrower spectrum.
Quality of the evidence
We considered the body of available evidence as having very low to moderate quality owing to absence of methods to prevent errors
during studies or absence of information about such methods, as well as possibly insufficient numbers of studies and patients per
outcome. Additionally, the authors of most studies worked as consultants and/or received payments from companies involved in the
procalcitonin analysis.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Patient or population: adult pat ients with sepsis, severe sepsis and sept ic shock
Settings: emergency departments, as well as general medical and surgical, academic and non-academic ICUs f rom Australia, Brazil, China, Czech Republic, France, Germany,
Indonesia and Switzerland
Intervention: PCT versus non-PCT (standard care or CRP: primary outcomes)
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with non-PCT
(standard care or CRP:
primary outcomes)
Risk with PCT
Mortality at longest fol-
low-up
Study populat ion RR 0.81
(0.65 to 1.01)
1156
(10 RCTs)
⊕⊕©©
Lowa
70% of studies (7/
10) were considered to
have high risk of bias in
at least 2 criteria, 50%
(5/ 10) low risk of bias
in at least 3 criteria and
50% (5/ 10) unclear risk
of bias in at least 1 crite-
rion, including random-
izat ion
We observed no asym-
metry in the funnel plot.
261 per 1000 211 per 1000
(169 to 263)
Mortality at 28 days Study populat ion RR 0.89
(0.61 to 1.31)
316
(4 RCTs)
⊕⊕©©
Lowb
25% of studies (1/
4) were considered to
have unclear risk of
bias for random se-
quence generat ion, 25%
(1/ 4) unclear risk of
bias for allocat ion con-
cealment and 100% (4/
4) unclear or high risk of
bias for blinding of par-
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t icipants and outcome
assessors
Conf idence
interval was considered
relat ively high (f rom 0.
61 to 1.31)
250 per 1000 223 per 1000
(153 to 328)
Mortality at ICU dis-
charge
Study populat ion RR 1.03
(0.50 to 2.11)
506
(3 RCTs)
⊕⊕©©
Lowb
All studies (3/ 3) were
considered to have low
risk of bias for ran-
dom sequence genera-
t ion, 33% (1/ 3) high risk
of bias for allocat ion
concealment and 100%
(3/ 3) unclear or high
risk of bias for blinding
of part icipants and out-
come assessors
I2 = 49% (heterogeneity
test).
Relat ively large conf i-
dence interval was 0.50
to 2.11.
97 per 1000 99 per 1000
(48 to 204)
Mortality at hospital
discharge
Study populat ion RR 0.98
(0.75 to 1.27)
805
(7 RCTs)
⊕⊕⊕©
Moderatec
28% of studies (2/
7) were considered to
have unclear risk of
bias for random se-
quence generat ion, 42.
8% (3/ 7) unclear or
high risk of bias for
allocat ion concealment
and 100% (7/ 7) unclear
or high risk of bias
for blinding of part ici-
pants and outcome as-
sessors
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199 per 1000 195 per 1000
(149 to 253)
Time receiving ant im i-
crobial therapy (days) -
mean (SD)
The mean time
receiving
ant im icrobial
therapy (days) -
mean (SD) was
8.09 (1.36) days
The mean time receiv-
ing ant im icrobial ther-
apy (days) - mean
(SD) in the intervent ion
group
was 1.28 days lower (1.
95 lower to 0.61 lower)
- 313
(4 RCTs)
⊕©©©
Very lowd
75% of studies (3/
4) were considered to
have unclear risk of
bias for both ran-
dom sequence genera-
t ion and allocat ion con-
cealment; 100% (4/ 4)
unclear or high risk of
bias for blinding of both
part icipants and out-
come assessors and
25% (1/ 4) unclear risk
of bias for incomplete
outcome data
I2 > 50% (heterogeneity
test indicat ing impor-
tant heterogeneity be-
tween studies)
Relat ively large 95%
conf idence interval was
0.61 to 1.95 days
Combined study results
show relevant reduc-
t ions in t ime receiv-
ing ant im icrobial ther-
apy of 1.28 days, which
varied f rom 0.61 days
to 1.95 days; individual
studies showed mean
dif ferences f rom 0.9 to
2 days
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Part ic-
ipants with ant im icro-
bial regimen changed
f rom a broad to a nar-
rower spectrum
Not available f rom primary studies
* The risk in the intervention group (and its 95% conf idence interval) is based on assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%
CI).
CI: conf idence interval; RR: risk rat io.
GRADE Working Group grades of evidence.
High quality: We are very conf ident that the true ef fect lies close to the est imate of ef fect.
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of ef fect but may be substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
a GRADE was downrated by two levels for risk of bias.
b GRADE was downrated by two levels: by one level for risk of bias; and by one level for imprecision.
c GRADE was downrated by one level for risk of bias.
d GRADE was downrated by four levels: by one level for risk of bias; by one level four imprecision; and by two levels for
inconsistency.
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B A C K G R O U N D
Description of the condition
Sepsis is defined as confirmed or suspected infection associ-
ated with a systemic inflammatory response syndrome (SIRS)
(Dellinger 2013). This condition can evolve to an acute organ
dysfunction or tissue hypoperfusion, known as severe sepsis, or
to persistent hypotension or vasopressor requirement, even after
adequate fluid resuscitation, known as septic shock (Bone 2009;
Dellinger 2013).
According to a comprehensive review, the occurrence of septic
conditions has been considered high, with incidence rates rang-
ing from 11 to 300/100,000 inhabitants per year, depending on
the severity of the systemic infection and the geographic region
of patients (Jawad 2012), with 15 to 19 million cases worldwide
reported per year (Adhikari 2010). Mortality rates can reach ap-
proximately 30% for sepsis, 50% for severe sepsis and 80% for sep-
tic shock (Jawad 2012; Salvo 1995; Silva 2004). However, studies
evaluating the incidence, prevalence and mortality of sepsis can
be biased strongly by the absence of rigour or even the lack of
adequate knowledge among healthcare professionals about iden-
tification of SIRS, sepsis, severe sepsis and septic shock (Assunção
2010; Klein 2012). Moreover, such conditions are associated with
high costs (Lagu 2012; Vaughan-Sarrazin 2011) and bad prog-
noses, including low quality of life and high mortality, even after
hospital discharge (Azevedo 2012; Cuthbertson 2013; Karlsson
2009).
Therapeutic approaches for sepsis include early and appropriate
antimicrobial agents, fluid resuscitation and strategies for achiev-
ing adequate blood (arterial and venous) pressure, myocardial
function, glucose levels and control of infectious foci (Dellinger
2013; Kuehn 2013; Machado 2013; Rivers 2012). However, the
success of such early therapeutic approaches depends on rapid
results of clinical and laboratory assessments, which usually in-
clude body temperature, heart rate, glycaemia, respiratory rate,
mental status, white blood cells, partial pressure of oxygen in ar-
terial blood, creatinine and lactate (Dellinger 2013; Levy 2003).
Therefore, clinicians have used additional biomarkers in an at-
tempt to diagnose the condition and drive the best therapeutic
strategies at the most appropriate moment for patients with sep-
sis. The most thoroughly investigated biomarkers for specific in-
fectious diseases are the interleukins, C-reactive protein (CRP),
procalcitonin (PCT) and neopterin (Tasdelen 2010; Tsalik 2012;
Uusitalo-Seppälä 2011). Some of these have been planned to be
rigorously evaluated in other Cochrane systematic reviews (Shaikh
2011; Suresh 2013).
Description of the intervention
During the course of an inflammatory event, including systemic
infection, several physiological and biochemical changes occur
(Hosein 2011; Lichtenstern 2012; Salluh 2011). One of these
changes is an increase in production of PCT, especially, but not
exclusively, in cases of bacterial infection (Chalupa 2011; Gendrel
1999; McCann 2012; Redl 2000; te Witt 2012). However, some
non-infectious conditions, such as trauma, surgery, hyperthermia
and neoplasm, can be associated with elevated procalcitonin levels
(Becker 2008). The peptide PCT is a precursor of the calcitonin
hormone, which is responsible for control of blood concentrations
of calcium. Under physiological conditions, PCT is produced by
the thyroid gland, but in inflammatory conditions, such as sep-
sis, virtually any type of cell can synthesize PCT (Morgenthaler
2003). Expression and liberation of PCT probably are stimulated
by different cytokines andmicrobial by-products (Zannoni 2012).
According to results from up to 30 studies included in two system-
atic reviews, serum PCT evaluation has revealed values of sensi-
tivity ranging from 55% to 97% (with pooled sensitivity of 77%)
and values of specificity from 55% to 93% (with pooled specificity
of 79%), as compared with definitions provided by the Ameri-
can College of Chest Physicians (ACCP)/Society of Critical Care
Medicine (SCCM)Consensus Conference, theGerman Sepsis So-
ciety or microbiological culture (Tang 2007;Wacker 2013). How-
ever, irrespective of accuracy properties, serum PCT evaluation is
an important health technology that should be evaluated in the
area of ’stratifiedmedicine research’ (Hingorani 2013). Serumpro-
calcitonin evaluation can possibly permit early detection of sepsis
and determination of the appropriate antimicrobial regimen, in-
cluding, but not restricted to, antimicrobial timing and spectrum.
An important outcome already observed with the serum procalci-
tonin evaluation can include lower hospital costs, but studies have
reported no consistent differences in mortality nor in length of
stay in the intensive care unit (ICU) (Maravi -Stojkovi 2011;
Schuetz 2012; Tang 2009).
How the intervention might work
Serum PCT evaluation has been proposed for early diagnosis and
accurate staging of sepsis, which can contribute to early decisions,
optimal care (Kenzaka 2012;Matthaiou 2012) and, consequently,
better outcomes for patients with sepsis, severe sepsis and septic
shock (Kumar 2010). Thus, the core ‘action mechanism’ of serum
PCT evaluation consists of altered decisions in the care of patients
with sepsis, severe sepsis and septic shock, based on test results,
with possible reduction in the risk of bad outcomes. The core
of this logical sequence of events is that serum PCT evaluation,
not drugs or usual care, is the technology being tested (Hingorani
2013).
Why it is important to do this review
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According to Rodger 2012, evaluation of the accuracy of a diag-
nostic test is not sufficient to prove its effectiveness, safety or effi-
ciency. Corroborating this concept, Hingorani 2013 emphasized
that the existence of a factor that predicts differential treatment
response does not guarantee that it will be effective when used as
a test in clinical practice to inform therapeutic decisions. There-
fore, it is of extreme importance that all available evidence on the
effectiveness, safety and efficiency of the serum PCT evaluation as
a health technology for patients with sepsis, severe sepsis and sep-
tic shock is scrutinized. We plan to perform a Cochrane system-
atic review of randomized controlled trials (RCTs) on this clinical
question that can be updated to summarize the main findings for
clinical practice.
O B J E C T I V E S
To assess the effectiveness and safety of serum PCT evaluation for
reducingmortality and duration of antimicrobial therapy in adults
with sepsis, severe sepsis or septic shock.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included RCTs and quasi-randomized trials (allocation not
considered strictly random), irrespective of language and publica-
tion year. We excluded cross-over trials because of the nature of
both the intervention and the clinical condition of interest for this
review.
Types of participants
We included adults (≥ 18 years old) with sepsis, severe sepsis or
septic shock, according to international definitions, irrespective
of health specialty (e.g. ward, outpatient clinic, ICU, emergency
department). We accepted the following definitions.
1. Sepsis: confirmed or suspected infection associated with a
systemic inflammatory response syndrome (SIRS).
2. Severe sepsis: sepsis associated with acute organ dysfunction.
3. Septic shock: sepsis associated with tissue hypoperfusion
and persistent hypotension, or vasopressor requirement, even
after adequate fluid resuscitation (Bone 2009; Dellinger 2013).
Types of interventions
We considered studies that performed serum PCT evaluation in at
least one comparison group. We expected three possible compari-
son groups based on diagnostic and staging methods: (i) standard
methods used routinely to diagnose and stage sepsis; (ii) serum
PCT evaluation or PCT-guided therapy algorithm; and (iii) other
biomarkers (e.g. CRP, interleukins, pentraxin). On the basis of
these groups, we expected the following possible comparisons.
1. i + ii versus i.
2. i + ii versus i + iii.
3. i + ii + iii versus i.
4. i + ii + iii versus i + iii.
5. i + ii versus i + ii (different PCT-guided therapy algorithms).
Types of outcome measures
Primary outcomes
1. Mortality at up to 28 days, in the ICU, in hospital (from
sepsis or all causes) and at longest follow-up.
2. Time receiving antimicrobial therapy (in days) or quantity
(volume) of antimicrobial agents received.
3. Change in antimicrobial regimen from a broad to a
narrower spectrum.
Secondary outcomes
1. Hospital length of stay (days).
2. ICU length of stay (days).
3. Clinical severity of participant’s condition, assessed by
validated instruments such as the Acute Physiology and Chronic
Health Evaluation II (APACHE II) and the Sequential Organ
Failure Assessment (SOFA).
4. New infection, as defined by a new SIRS event by reason of
a new micro-organism detected after resolution of the initial
infection, involving the same infectious focus or a different
infectious focus; or reinfection, as defined by a new SIRS event
by reason of the same micro-organism detected after resolution
of the initial infection, involving the same infectious focus or a
different infectious focus.
5. Duration of mechanical ventilation (days).
Search methods for identification of studies
Electronic searches
Two review authors searched the Cochrane Central Register of
ControlledTrials (CENTRAL; 2015, Issue 7; Appendix 1);MED-
LINE (via PubMed, 1950 to July 2015; Appendix 2); Embase
(Ovid SP, 1980 to July 2015; Appendix 3); the Cumulative Index
toNursing and AlliedHealth Literature (CINAHL; EBSCO host,
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1982 to July 2015); and the Latin American Caribbean Health
Sciences Literature (LILACS via BIREME, 1982 to July 2015;
Appendix 5). Additionally, we reran the search in October 2016.
We added three new studies of interest to a list of Studies awaiting
classification and will incorporate these into formal review find-
ings during the review update.
We used a systematic and sensitive search strategy with search
terms for sepsis, severe sepsis, septic shock, procalcitonin evalua-
tion and randomized controlled trials (Appendix 2). We applied
no restrictions based on language or date of publication.
Searching other resources
We handsearched the reference lists of reviews, randomized and
non-randomized studies and editorials to look for additional stud-
ies.We contacted the lead authors of studies and experts in this field
to ask about missed, unreported or ongoing studies. We searched
for ongoing clinical trials and unpublished studies on the follow-
ing Internet sites (July 2015).
1. http://www.controlled-trials.com.
2. http://clinicaltrials.gov.
3. http://www.centerwatch.com.
Data collection and analysis
Selection of studies
After excluding duplicates, two review authors (BNGA and RBA)
independently assessed all titles and abstracts of studies retrieved
by the search strategy to determine their relevance for possible
inclusion. We resolved disagreements by discussion with a third
review author (RS).
Data extraction and management
Two review authors (BNGA and RBA) independently extracted
data from each study using a previously prepared data extraction
form that includes specific characteristics of each study (Appendix
6). We described as the ‘primary reference’ the first publication
of each study with more than one publication, and as ‘secondary
references’ all other publications, but we extracted data from all
references onto the same extraction sheet.
Assessment of risk of bias in included studies
Two review authors (RBA and BNGA) assessed risk of bias on the
basis of criteria described in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011). We assessed the quality
of RCTs according to the following domain-based evaluation.
1. Was the allocation sequence adequately generated?
2. Was allocation adequately concealed?
3. Was knowledge of the allocated intervention adequately
prevented during the study?
4. Were incomplete outcome data adequately addressed?
5. Are reports of the study free of the suggestion of selective
outcome reporting?
6. Was the study apparently free of other problems that could
put it at high risk of bias?
We classified each domain as ‘low risk of bias’ when the authors of
primary studies reported methods to prevent bias; as ‘unclear risk
of bias’ when risk of bias was uncertain; and as ‘high risk of bias’
when the authors of primary studies clearly had not prevented risk
of bias.
We reported these assessments for each individual study in the
‘Risk of bias’ table.
We contacted study author(s) to ask for clarification if we had any
uncertainty regarding study data.
Measures of treatment effect
For dichotomous data (e.g. mortality rates), we calculated risk ra-
tios (RRs). In case the effect estimates were statistically signifi-
cant, we calculated the number needed to treat for an additional
beneficial outcome (NNTB) (Christensen 2006). We calculated
mean differences (MDs) for continuous data (e.g. hospital length
of stay, ICU length of stay). However, some data were presented in
isolation, as they were reported in the primary studies. Thus, we
reported some continuous data as medians and respective ranges
or interquartile ranges (e.g. time receiving antimicrobial therapy,
hospital and ICU length of stay, duration of mechanical ventila-
tion in days). Similarly, we presented some dichotomous data as
hazard ratios (HRs) with their respective 95% confidence intervals
(CIs) (e.g. antibiotic therapy discontinuation). We reported effect
estimates from continuous and dichotomous data as P values and
95% CIs for both individual and pooled data (see Data synthesis).
We planned to contact study author(s) to ask for clarification if
we had any uncertainty regarding estimated effects (including but
not restricted to data reported only in graphs).
Unit of analysis issues
The individual participant was the unit of analysis inclusively in
analyses of cluster-randomized controlled trials. When this was
the case, we used direct effect estimates obtained from individual
studies (and respective confidence intervals) and combined them
in a meta-analysis using the generic inverse variance method.
Dealing with missing data
If it was possible to assess the real number of randomly assigned
participants (by reading the publication or by contacting study
authors), we intended to perform intention-to-treat (ITT) anal-
yses for dichotomous data. We assumed the worst outcome for
all participants who withdrew from/dropped out of the study (see
Sensitivity analysis).
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Assessment of heterogeneity
We evaluated the consistency of estimated effects from individual
studies by calculating I2 (Higgins 2011). The I2 statistic describes
approximately the proportion of variation in point estimates that
is due to heterogeneity rather than to sampling error.We evaluated
the degree of heterogeneity according to the following thresholds.
1. 0% to 40%: may not be important.
2. 30% to 60%: may represent moderate heterogeneity.
3. 50% to 90%: may represent substantial heterogeneity.
4. 75% to 100%: represents considerable heterogeneity.
Assessment of reporting biases
We planned to assess reporting bias by visually inspecting the fun-
nel plot to detect the presence of asymmetry, if we included in the
review more than 10 studies per outcome.
Data synthesis
Meta-analytical data synthesis
When more than one study reported continuous and dichoto-
mous data, we pooled results by using the fixed-effect meta-anal-
ysis model when we noted no substantial statistical heterogene-
ity, and the random-effects meta-analysis model when statisti-
cal heterogeneity between included studies was substantial (see
Assessment of heterogeneity).We pooled continuous data by using
the weighted average of differences between comparison groups,
wherein outcomes published for more than one study were as-
sessed on the same scales. If data were reported on different scales
that could not be adjusted to a uniform scale, we planned to anal-
yse them by using the standardized mean difference (SMD). We
performed a post hoc trial sequential analysis (TSA) to quantify
the reliability of cumulative data in meta-analyses (Brok 2009;
Wetterslev 2008).
Synthesis of dichotomous and continuous data without
sufficient information to insert into a forest plot
When estimated effects were reported without sufficient informa-
tion for insertion into a forest plot, such as numbers of partici-
pants, numbers of events, means, standard deviations and stan-
dard errors, as well as effect estimates for non-parametric data (e.g.
range, median, percentiles), we reported the data separately in ta-
bles in theData collection and analysis section (not in forest plots).
Synthesis of the quality of the body of evidence
We used the principles of the GRADE approach (Guyatt 2008)
to assess the quality of the body of evidence for our primary out-
comes of mortality at 28 days, mortality at ICU discharge, mor-
tality at hospital discharge and time receiving antimicrobial ther-
apy. We imported effect estimates from RevMan 5.3 to GRADE
profiler (GRADEpro 2014) to create Summary of findings for the
main comparison. This table provides outcome-specific informa-
tion concerning the overall quality of evidence from studies in-
cluded in the comparison, themagnitude of effect of interventions
examined and the sum of available data on outcomes that we con-
sidered. The GRADE approach appraises the quality of a body of
evidence according to the extent to which one can be confident
that an estimate of effect or association reflects the item assessed.
The quality of a body of evidence is based on different items,
which reflect within-study risk of bias (methodological quality),
directness of evidence, heterogeneity of data, precision of effect
estimates and risk of publication bias. Thus, we considered each
of these items as having ’no limitation’, ’serious limitation’ or ’very
serious limitation’ (by downgrading them respectively for one or
two levels), resulting in one of the following four overall qualities
of evidence for each outcome: ’high’, ’moderate’, ’low’ or ’very low’
quality.
Subgroup analysis and investigation of heterogeneity
We planned to compare the possible subgroups below.
1. Diagnostic criteria for sepsis, severe sepsis and septic shock.
2. Participants with sepsis, severe sepsis or septic shock.
3. Infection foci, including respiratory, surgical, bloodstream,
catheter, urinary and others.
4. Different cut-off points for PCT to guide the antimicrobial
regimen for any absolute reduction in PCT level, any relative
reduction in PCT level or any threshold of PCT level.
5. Participants attended by different health specialties (e.g.
emergency, ICU, ward).
6. PCT-guided antibiotic commencement versus PCT-guided
antibiotic stewardship. It is important to note that multiple
subgroup analyses may generate misleading results, but the
review authors judged it improbable that included studies would
provide sufficient information to permit analyses of all six of
these subgroups.
However, we performed no subgroup analyses in this version of
the review because of (1) the absence of statistical heterogeneity
in the meta-analysis or (2) the absence of a sufficient number of
studies with the same specific characteristics to be combined in
the same subgroup.
Sensitivity analysis
We planned to examine the robustness of results by excluding and
including trials on the basis of risk of bias of included studies,
and by considering quasi-randomized controlled trials. We also
planned to compare random-effects and fixed-effect estimates only
for the primary outcomes, as well as intention-to-treat analysis
versus available data analysis (refer to Dealing with missing data).
However, risks of bias were highly diverse among the included
studies, no quasi-RCT was localized and studies were clinically
and methodologically heterogeneous, which justified the use of
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random-effects meta-analysis only. Thus, we performed sensitivity
analysis only for ITT versus available data analyses for the present
version of this systematic review. We assumed poor outcomes for
missingdata, as supported by theCochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011).
R E S U L T S
Description of studies
Results of the search
The search across all databases yielded 1068 titles. When we ex-
cluded duplicate references, we found that we had 740 articles.
Of these 740 articles, we excluded 699 because they did not focus
on the use of procalcitonin for adults with sepsis, severe sepsis or
septic shock, as stated in their titles or abstracts. Of the remaining
41 full-text articles, we excluded 25 that were derived from 22
studies because of study design. Thus, 16 articles had the poten-
tial to be included in the review (Figure 1). Of these 16 articles,
we obtained four (derived from three studies) through the search
strategy that we reran across all databases in October 2016 (Bloos
2016; de Jong 2016; Najafi 2015). We contacted the main au-
thors of four of the remaining 12 articles (Dharaniyadewi 2013;
Hochreiter 2009; Liu 2013; Schroeder 2009) to request further
information, as outlined in the Characteristics of included studies
table.
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Figure 1. Study flow diagram.
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Included studies
We included in this review 12 articles derived from 10 trials (1215
participants). These trials were carried out in France (one; Annane
2013), Brazil (two; Deliberato 2013; Oliveira 2013), Indonesia
(one; Dharaniyadewi 2013), Germany (two; Hochreiter 2009;
Schroeder 2009), China (one; Liu 2013), Switzerland (one; Nobre
2008), Czech Republic (one; Svoboda 2007) and Australia (one;
Shehabi 2014). Five trials were multi-centre RCTs (Annane 2013;
Nobre 2008; Oliveira 2013; Shehabi 2014; Svoboda 2007). Three
studies included participants from surgical ICUs (Deliberato
2013; Hochreiter 2009; Schroeder 2009), but Schroeder 2009
specifically considered participants who had undergone abdomi-
nal surgery. Nobre 2008 included participants from both general/
medical and surgical ICUs. Svoboda 2007 included participants
with trauma. Three trials were carried out in academic health ser-
vices (Liu 2013; Nobre 2008; Oliveira 2013). One trial (Shehabi
2014) referred to its participants as derived from both academic
and non-academic ICUs.
Although they showed some variation in their manner of describ-
ing the inclusion criteria, all trials included in this systematic re-
view mentioned adults with confirmed or presumed sepsis, severe
sepsis and/or septic shock, according to criteria usually accepted
by international consensus (ACCP/SCCMConsensus Conference
Committee 1992; Bone 1992; Levy 2003).
The procalcitonin algorithms were relatively diverse. In gen-
eral, the authors used PCT drops from 25% to 90% together
with PCT thresholds raging from 0.1 to 2.0 ng/mL (Annane
2013; Deliberato 2013; Hochreiter 2009; Liu 2013; Nobre 2008;
Oliveira 2013; Schroeder 2009; Shehabi 2014; Svoboda 2007).
Four authors have also considered other clinical signs and symp-
toms (Hochreiter 2009; Schroeder 2009; Shehabi 2014; Svoboda
2007). Dharaniyadewi 2013 provided no PCT algorithm in
the paper or in the protocol available from Clinical Trials.gov
(NCT01862185).
Control arms were referred to most commonly as ’standard care’,
which was generally based on local epidemiology and suscepti-
bility of micro-organisms, infectious foci, routine clinical evalua-
tion or other criteria based on different guidelines previously im-
plemented in the health service (Annane 2013; Deliberato 2013;
Dharaniyadewi 2013; Hochreiter 2009; Liu 2013; Nobre 2008;
Svoboda 2007). Just one study used a CRP-guided algorithm,
in which antimicrobial therapy was stopped when CRP levels
dropped by > 50% or when CRP < 25 mg/dL was reached but
the participant’s PCT concentrations were not known (Oliveira
2013).
For more detailed information about the studies included in this
review, please refer to Characteristics of included studies.
Excluded studies
On the basis of study design and inclusion criteria, we excluded 25
articles that had been generated from 22 studies. Six were system-
atic reviews (Kopterides 2010; Mann 2011; Prkno 2013; Sandifer
2012; Schuetz 2011; Soni 2013); three were narrative reviews
(Pantelidou 2015; Schuetz 2013; Ternhag 2010); three RCTs in-
cluded neonates (Kolici 2013; Stocker 2010a; Stocker 2010b); one
RCT had inclusion criteria strict for febrile neutropenia (Lima
2016); three were RCTs (which generated six articles) with inclu-
sion criteria not specific for sepsis, severe sepsis and/or septic shock
(Bouadma 2010; Jensen 2011; Layios 2012); two used a retro-
spective study design (Bodmann 2016; Kiehntopf 2011); and four
performed economic evaluations (Bréchot 2015; Harrison 2015;
Kip 2015; Westwood 2015).
For more detailed information about the excluded studies, please
refer to the Characteristics of excluded studies table.
Studies awaiting classification
Although results of this systematic review are based on the search
from July 2015, a new search carried out inOctober 2016 revealed
three new studies of interest, whichwewill incorporate into formal
review findings during the review update. Twomulti-centre (Bloos
2016; de Jong 2016) and one single-centre (Najafi 2015) RCTs
were carried out in 35 medical ICUs in Germany (Bloos 2016), 15
in Netherlands (de Jong 2016) and one in Tehran (Najafi 2015).
These trials included a total of 2695 participants. Bloos 2016
was the only 2 × 2 factorial study that included use of high-dose
intravenous sodium selenite in patients with severe sepsis or septic
shock, according to ACCP/SCCM criteria. The other two studies
included participants with an antimicrobial regimen initiated for
suspected or proven infection on admission or during ICU stay
(de Jong 2016) and for SIRS (Najafi 2015).
The interventions offered by Bloos 2016 consisted of a PCT-based
algorithm (with or without sodium selenite) versus antimicrobial
therapy, according to the discretion of the responsible physician
(with noPCTusage), alsowith or without sodium selenite. de Jong
2016 and Najafi 2015 randomized participants to PCT-guided
antimicrobial therapy via different algorithms or to standard treat-
ment (non-PCT groups). These three studies measured mortality
at different follow-up times and in different settings (e.g. at 28
days, at one year, in ICU, in hospital). For additional details, see
Characteristics of studies awaiting classification.
Ongoing studies
We found no studies awaiting classification.
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Risk of bias in included studies
Please see Characteristics of included studies, Figure 2 and Figure
3.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Random sequence generation
We considered six trials as having low risk of bias regarding random
sequence generation because study authors used randommethods.
The most frequently reported method was based on electronic
random processes generally referred to as “computer-generated
random numbers” (Annane 2013; Nobre 2008; Oliveira 2013;
Shehabi 2014; Svoboda 2007), but Deliberato 2013 reported that
two authors of the trial randomly drew folders from a black box
to assign participants to a “PCT group” or a “standard group”. We
considered the other four trials to have unclear risk of bias because
they did not specify anymethodof randomization (Dharaniyadewi
2013; Hochreiter 2009; Liu 2013; Schroeder 2009).
We tried without success to contact the authors of four trials by
email to obtain detailed information about the method used for
random sequence generation (Dharaniyadewi 2013; Hochreiter
2009; Liu 2013; Schroeder 2009) (please refer to Characteristics
of included studies for details).
Allocation concealment
Three trials provided no information regarding allocation conceal-
mentmethods (Dharaniyadewi 2013; Liu 2013; Schroeder 2009),
thus we considered them as having unclear risk of bias. Four tri-
als used methods associated with low risk of bias for allocation
concealment (Annane 2013; Nobre 2008; Shehabi 2014; Svoboda
2007). Annane 2013 and Shehabi 2014 reported the use of web-
based central randomization. Two trials used opaque, sealed and
numbered envelopes (Nobre 2008; Svoboda 2007).We considered
two trials as having high risk of bias (Deliberato 2013; Hochreiter
2009). One of them used a method that does not prevent ex-
emption in the randomization process because study authors per-
formed randomization by drawing folders from a box to assign
participants to comparison groups (Deliberato 2013). Given that
Hochreiter 2009 provided no description of the method used to
randomize participant assignments, and that study authors clearly
reported the study as open label, we have also assumed that this
study has high risk of bias.
We tried without success to contact the authors of four trials by
email to obtain detailed information about the method used for
allocation concealment (Dharaniyadewi 2013; Hochreiter 2009;
Liu 2013; Schroeder 2009).
Blinding
Performance bias
Personnel involved in the trials were clearly unblinded to assign-
ments in six trials (Annane 2013; Deliberato 2013; Hochreiter
2009; Nobre 2008; Oliveira 2013; Shehabi 2014), thus we con-
sidered these trials as having high risk of performance bias. We
classified four trials as having unclear risk of performance bias be-
cause study authors provided no information regarding blinding
of personnel and participants (Dharaniyadewi 2013; Liu 2013;
Schroeder 2009; Svoboda 2007).
Detection bias
Four trials (Dharaniyadewi 2013; Liu 2013; Schroeder 2009;
Svoboda 2007) provided no information with regard to blinding
of outcome assessors, and we considered them as having unclear
risk of detection bias. We considered six trials as having high risk of
detection bias because study authors reported that outcome asses-
sors were not blinded (Annane 2013; Deliberato 2013;Hochreiter
2009; Nobre 2008; Oliveira 2013 ;Shehabi 2014).
Incomplete outcome data
We considered all included trials as having low risk of attrition
bias because they described a clear flow of participants from ran-
domization to outcome assessment, along with low withdrawal
rates, with the exception of one trial with unclear risk of attrition
bias (Liu 2013), which provided neither information about with-
drawals nor a description of a clear flow of participants within the
trial.
Selective reporting
We considered all trials as having low risk of reporting bias because
investigators evaluated clinically relevant outcomes. Additionally,
four trials made their protocols available along with previously
planned outcomes in an electronic repository of research protocols
(clinicaltrials.gov) (Annane 2013; Nobre 2008; Oliveira 2013;
Shehabi 2014).
Other potential sources of bias
Nine trials were associated with no suspected additional source of
bias, and we considered them as having low risk of bias (Annane
2013; Deliberato 2013; Hochreiter 2009; Liu 2013; Nobre 2008;
Oliveira 2013; Schroeder 2009; Shehabi 2014; Svoboda 2007),
along with one study for which the authors did not provide a
detailed PCT algorithm for dealing with antimicrobial therapies
(Dharaniyadewi 2013).
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Effects of interventions
See: Summary of findings for the main comparison PCT versus
non-PCT (standard care or CRP: primary outcomes) for reducing
mortality in adult patients with sepsis, severe sepsis and septic
shock
Primary outcomes
1. Mortality
1.1 Mortality at longest follow-up
Ten trials when combined into a meta-analysis (Annane 2013;
Deliberato 2013; Dharaniyadewi 2013; Hochreiter 2009; Liu
2013;Nobre 2008;Oliveira 2013; Schroeder 2009; Shehabi 2014;
Svoboda 2007) showed no significant differences in mortality at
longest follow-up between PCT (124/573; 21.6%) and non-PCT
(152/583; 26.1%) groupswith RR of 0.81 (95%CI 0.65 to 1.01; I
2 =10%;Analysis 1.1).One trial comparedmortality rates between
the procalcitonin group (21/49; 42.8%) and the CRP-monitoring
group (21/45; 46.6%) (Oliveira 2013) and reported no differences
between comparison groups (RR 0.92, 95% CI 0.59 to 1.44). We
downgraded the evidence from high to low quality because risk of
bias from primary studies was downgraded by two levels.
A post hoc TSA for mortality at longest follow-up with inclusion
of trials with no events (zero event adjustment of 0.001 constant),
type 1 error of 5% and power of 80% resulted in a TSA-adjusted
RR of 0.80 (95% CI 0.65 to 0.98; I2 = 0%; diversity (D2) =
0%). On the basis of mortality incidence of 26.07% in the control
arm and risk reduction of 17.1%, the required information size is
2853. With 1156 participants included at this time, only 40.52%
of the required information size has been reached. Additionally,
TSA is designed for trials with low risk of bias, and given that all
included trials had high risk of bias, the true required information
size may very well be higher than reported here, but a large trial
with low risk of bias in favour of the intervention may equally
reduce the required information size. Additionally, the TSA figure
shows that the conventional boundary was not crossed and no
significant benefit favoured the intervention (Figure 4).
Figure 4. Trial sequential analysis for mortality at longest follow-up (available data analysis).
1.2 Mortality at 28 days
Four trials combined into a meta-analysis (Liu 2013; Nobre 2008;
Oliveira 2013; Svoboda 2007) showed no significant differences
in mortality at 28 days between PCT (37/160; 23.1%) and non-
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PCT (39/156; 25.0%) comparison groups (RR0.89, 95%CI 0.61
to 1.31; four trials; N = 316; I2 = 0%) (Analysis 1.2). One trial
comparedmortality rates between the procalcitonin group (16/49;
32.6%) and the CRP-monitoring group (15/45; 33.3%) (Oliveira
2013) and reported no difference between comparison groups (RR
0.98, 95% CI 0.55 to 1.74). We downgraded the evidence from
high to low quality because risk of bias from primary studies was
downgraded by one level, and imprecision was downgraded by
one level.
1.3 Mortality at ICU discharge
Afterwe combined effect estimates from three trials (Annane2013;
Deliberato 2013; Shehabi 2014) in a meta-analysis, we found no
significant differences in mortality at ICU discharge (RR 1.03,
95% CI 0.50 to 2.11; I2 = 49%) (Analysis 1.3). We downgraded
the evidence from high to low quality because risk of bias and
imprecision from primary studies were downgraded by one level.
1.4 Mortality at hospital discharge
Irrespective of whether comparison arms provided procalcitonin
versus non-procalcitonin (standard care) or procalcitonin ver-
sus CRP-guided antimicrobial therapy (Oliveira 2013), a meta-
analysis combining seven trials (Annane 2013; Deliberato 2013;
Hochreiter 2009; Nobre 2008; Oliveira 2013; Schroeder 2009;
Shehabi 2014) showed absence of differences between them (RR
0.98, 95% CI 0.75 to 1.27; I2 = 0%; Analysis 1.4). We down-
graded the evidence from high to moderate quality because risk of
bias and imprecision from primary studies were downgraded by
one level.
2. Time receiving antimicrobial therapy (in days) or quantity
(volume) of antimicrobial agents received
A meta-analysis that combined four trials evaluating the duration
of antimicrobial therapy in days (Hochreiter 2009; Oliveira 2013;
Liu 2013; Schroeder 2009) resulted in a reduction of -1.28 mean
days (95%CI -1.95 to -0.61; I2 = 86%) in the procalcitonin group
as compared with the non-procalcitonin group (Analysis 1.5).
Even after Oliveira 2013 was removed from the analysis because
investigators compared procalcitonin versus CRP, heterogeneity
remained and the effect estimate did not change significantly (-
1.60 mean days, 95% CI -2.18 to -1.01; I2 = 84%). When we
combined only Hochreiter 2009 and Schroeder 2009 in a meta-
analysis, the inconsistency test (I2 statistic) dropped to 0%, but
the effect estimate remained very close to that observed before
Liu 2013 and Oliveira 2013 were excluded, as shown by a mean
reduction of -1.91 days (95% CI -2.29 to -1.52; I2 = 0%). Still
with regard to duration of antibiotic treatment, Oliveira 2013
observed 13median days (interquartile range (IQR) 7 to 18) in the
procalcitonin group and eight median days (IQR 6 to 18) in the
CRP-guided antimicrobial therapy group, but without statistical
significance in the comparison between groups (P = 0.183), as
reported by study authors (Analysis 1.6).
Wedowngraded the evidence fromhigh to very lowquality because
risk of bias was downgraded by one level, imprecision by one level
and inconsistency by two levels.
3. Participants with change in antimicrobial regimen from a
broad to a narrower spectrum
Nostudymade available sufficient and comparable informationon
participants who had their antimicrobial regimen changed from a
broad to a narrower spectrum.
Secondary outcomes
Hospital length of stay (days)
With the exception of Oliveira 2013, other trials (Annane 2013;
Deliberato 2013; Nobre 2008; Shehabi 2014) showed results
favouring the procalcitonin groups, with differences in median
values ranging from two days to seven days, but found no statisti-
cal significance (Analysis 2.1). However, another study (Liu 2013)
showed results favouring the procalcitonin group (27.0mean days;
standard deviation (SD) = 4.9) as compared with the non-procal-
citonin group (32.0 mean days; SD = 5.4), with a statistically sig-
nificant difference between comparison groups (-5.00 days, 95%
CI -7.24 to -2.76; P < 0.0001; Analysis 2.1).
ICU length of stay (days)
Four trials evaluated mean days in the ICU (Hochreiter 2009; Liu
2013; Schroeder 2009; Svoboda 2007), resulting in a pooled effect
that favoured the procalcitonin group (-2.05 days, 95% CI -3.14
to -0.97; I2 = 0%; Analysis 2.2).
Five other studies evaluated time in the ICU as median values with
respective IQRs and P values (Annane 2013; Deliberato 2013;
Nobre 2008; Oliveira 2013; Shehabi 2014). Four trials reported
directions of effect favouring the procalcitonin groups, with dif-
ferences between median values ranging from a half-day to two
days, but only Nobre 2008 found a statistically significant differ-
ence (0.03) between the procalcitonin group (median of 3 days;
IQR 1 to 18) and the non-procalcitonin group (median of 5 days;
IQR 1 to 30). Oliveira 2013 found the opposite direction of effect
favouring the non-procalcitonin group (median of 12 days; IQR
7 to 18) as compared with the procalcitonin group (median of 14
days; IQR 9 to 24), with no statistically significant differences (P
= 0.164; Analysis 2.3).
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Clinical severity of participant’s condition
Svoboda 2007 reported SOFA scores at day 28 as means and re-
spective standard deviations, resulting in a borderline statistically
non-significant difference in means of -1.40 (95% CI -2.82 to
0.02; P = 0.5) in favour of the procalcitonin group (Analysis 2.4).
Annane 2013 also evaluated SOFA scores at days three and five but
found no statistically significant differences (Analysis 2.5; Analysis
2.6). Schroeder 2009 analysed the SOFAmax , defined as the high-
est sequential failure assessment score, during the period of ob-
servation but found a statistically non-significant difference be-
tween comparison groups, as shown in Analysis 2.7; and Liu 2013
found other non-significant difference while evaluating APACHE
II (Analysis 2.8).
New infection or reinfection
After the results of Deliberato 2013, Nobre 2008 and Oliveira
2013 were combined, themeta-analysis revealed a higher but non-
significant risk of reinfection in the procalcitonin group (5/100;
5.0%) as compared with the non-procalcitonin group (3/113;
2.65%) with a risk ratio of 1.84 (95% CI 0.43 to 7.89; I2 = 0%;
Analysis 2.9).
Duration of mechanical ventilation (days)
Three trials (Annane 2013; Shehabi 2014; Svoboda 2007) found
no statistically significant differences between comparison groups,
although effects favoured procalcitonin in Annane 2013 and
Svoboda 2007 (Analysis 2.10).
Other outcomes of potential interest
After we had extracted all estimates of effects from the primary
studies, we had an excess of 56 dependent variables on which to
base our comparisons between procalcitonin and non-procalci-
tonin groups (standard care or CRP), as shown in Analysis 3.1 to
Analysis 3.38. However, we observed significant effects in favour
of procalcitonin-guided antimicrobial therapy in only eight vari-
ables related to mortality at 14 days (Analysis 3.2), in empirical
antibiotic initiation (Analysis 3.12; Analysis 3.13) and in an addi-
tional five ways of measuring time of antimicrobial usage (Analysis
3.23; Analysis 3.28; Analysis 3.29; Analysis 3.30; Analysis 3.32).
As a probable consequence of more rational antimicrobial usage,
two study authors reported relevant reductions in costs associ-
ated with procalcitonin-guided antimicrobial therapy. Deliberato
2013, for example, reported a reduction in total costs of an-
tibiotics from USD 42,397.00 in the standard care group to
USD10,608.00 in the procalcitonin-guided antimicrobial therapy
group, corresponding to an approximate reduction in cost with
antimicrobials of 75% (Analysis 3.39), as well as a mean cost with
antibiotics plus PCT kits per participant of USD 977.40 against
USD1367.64 in the non-procalcitonin group, corresponding to
an approximate cost reduction of 28% (Analysis 3.40). Schroeder
2009 reported an important reduction of 17% in costs of antibi-
otic treatment associated with procalcitonin-guided antimicrobial
therapy as compared with non-procalcitonin-guided treatment (P
< 0.01) (Analysis 3.41).
Assessment of reporting biases
We explored publication bias for mortality at longest follow-up
by using the funnel plot. Visual inspection of the funnel plot
(Figure 5) revealed no apparent influence (tendency) of small stud-
ies leading to more or less beneficial intervention effect estimates
(Higgins 2011). Thus, we consider publication bias improbable
at the present version of this systematic review.
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Figure 5. Funnel plot of comparison: 1 PCT versus non-PCT (standard care or CRP: primary outcomes),
outcome: 1.1 Mortality at longest follow-up.
Sensitivity analysis
Sensitivity analysis 1. Imputing missing data with mortality
versus available data analysis in “Mortality at longest follow-
up” outcome
We performed a sensitivity analysis to observe the effects of im-
puting missing data with poor outcomes in the analysis of our pri-
mary outcome of “Mortality at longest follow-up” (Higgins 2011).
Our ITT analysis showed no significant differences in mortality at
longest follow-up between PCT (164/613; 26.7%) and non-PCT
(171/602; 28.4%) comparison groups (RR 0.98, 95% CI 0.73 to
1.32; I2 = 56%; Analysis 4.1), as in the available data analysis (RR
of 0.81, 95% CI 0.65 to 1.01; I2 = 10%; Analysis 1.1).
We performed additional post hoc sensitivity analyses to test the
effects of including three studies with inclusion criteria not specific
for sepsis, severe sepsis or septic shock, as previously planned in
our protocol (Bouadma 2010; Jensen 2011; Layios 2012) and as
shown in Sensitivity analyses 2, 3 and 4 below.
Sensitivity analysis 2. Mortality at longest follow-up in
studies with inclusion criteria not specific for sepsis, severe
sepsis or septic shock
Inclusion of Bouadma 2010, Jensen 2011 and Layios 2012
in a meta-analysis of 13 trials (Annane 2013; Bouadma 2010;
Deliberato 2013; Dharaniyadewi 2013; Hochreiter 2009; Jensen
2011; Layios 2012; Liu 2013; Nobre 2008; Oliveira 2013;
Schroeder 2009; Shehabi 2014; Svoboda 2007) revealed no signif-
icant differences in mortality at longest follow-up between PCT
(435/1742; 24.9%) and non-PCT (460/1744; 26.3%) compari-
son groups (RR 0.92, 95%CI 0.81 to 1.05; I2 = 11%; Figure 6) as
compared with included studies (RR 0.81, 95% CI 0.65 to 1.01;
I2 = 10%; Analysis 1.1).
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Figure 6. Sensitivity analysis including Bouadma 2010, Jensen 2011 and Layios 2012: 1 PCT versus non-PCT
(standard care or CRP: primary outcomes), outcome: 1.1 Mortality at longest follow-up (Analysis 1.1).
Sensitivity analysis 3. Mortality at 28 days in studies with
inclusion criteria not specific for sepsis, severe sepsis or
septic shock
Inclusion of Jensen 2011 and Bouadma 2010 in a meta-analysis of
six studies (Bouadma 2010; Jensen 2011; Liu 2013; Nobre 2008;
Oliveira 2013; Svoboda 2007) revealed no significant differences
in mortality at 28 days between PCT (292/1071; 27.2%) and
non-PCT (294/1066; 27.6%) comparison groups (RR 0.98, 95%
CI 0.86 to 1.12; I2 = 0%; Figure 7) as compared with included
studies (RR 0.89, 95% CI 0.61 to 1.31; four trials; N = 316; I2 =
0%; Analysis 1.2).
Figure 7. Sensitivity analysis including Bouadma 2010 and Jensen 2011: 1 PCT versus non-PCT (standard
care or CRP: primary outcomes), outcome: 1.2 Mortality at 28 days (Analysis 1.2).
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Sensitivity analysis 4. Mortality at ICU discharge in studies
with inclusion criteria not specific for sepsis, severe sepsis or
septic shock
Inclusionof Layios 2012 in ameta-analysis of four studies (Annane
2013; Deliberato 2013; Layios 2012; Shehabi 2014) revealed no
significant differences in mortality at ICU discharge (RR 1.04,
95% CI 0.79 to 1.38; I2 = 0%; Figure 8) compared with included
studies (RR 1.03, 95% CI 0.50 to 2.11; I2 = 49%; Analysis 1.3).
Figure 8. Sensitivity analysis including Layios 2012: 1 PCT versus non-PCT (standard care or CRP: primary
outcomes), outcome: 1.3 Mortality at ICU discharge (Analysis 1.3).
D I S C U S S I O N
Summary of main results
Through our comprehensive search strategy, we retrieved 486 ar-
ticles. Twelve articles met our inclusion criteria but were generated
from 10 studies. This relatively small number of studies provided
59 dependent variables. Seventeen were related to primary and
secondary outcomes previously planned for this systematic review.
We did not omit the remaining 42 outcomes from this review
because we considered them to be of potential interest to readers,
including researchers and decision makers.
Primary outcomes
For mortality at 28 days, at intensive care unit (ICU) dis-
charge, at hospital discharge and at longest follow-up, included
studies were consistent in terms of showing absence of dif-
ferences between procalcitonin-guided and non-procalcitonin-
guided antimicrobial therapy (standard care or C-reactive protein
(CRP)-guided antimicrobial therapy) (Annane 2013; Deliberato
2013; Hochreiter 2009; Liu 2013; Nobre 2008; Oliveira 2013;
Schroeder 2009; Shehabi 2014; Svoboda 2007), with the excep-
tion of Dharaniyadewi 2013.
Three out of four trials (Hochreiter 2009; Liu 2013; Schroeder
2009) showed that duration of antimicrobial therapy was reduced
by more than one day, but one study (Oliveira 2013) showed
non-significant statistical differences that favoured CRP-guided
antimicrobial therapy. Additionally, Deliberato 2013 noted a sta-
tistically significant reduction of four days in duration of antimi-
crobial therapy associated with the procalcitonin group, measured
as median values; however, Annane 2013 did not observe such a
significant reduction in the time it took to receive antimicrobial
therapy.
Secondary outcomes
Liu 2013 showed a statistically significant reduction of five days
of stay in the hospital in the procalcitonin group. Annane 2013,
Deliberato 2013, Nobre 2008, Oliveira 2013 and Shehabi 2014
reported length of hospital stay as median values. Four of these
studies showed statistically non-significant reductions in favour
of procalcitonin groups, which varied from two to six days of
stay in the hospital (Annane 2013; Deliberato 2013; Nobre 2008;
Shehabi 2014).
Four studies reported more optimistic results for ICU length of
stay, with an approximate mean difference of two days in favour of
the procalcitonin groups (Hochreiter 2009; Liu 2013; Schroeder
2009; Svoboda 2007), but Oliveira 2013 observed non-significant
results. Annane 2013, Deliberato 2013, Nobre 2008, Oliveira
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2013 and Shehabi 2014 reported results asmedian values, but only
Nobre 2008 noted a significant difference of two days in favour
of the procalcitonin group.
Although participants in some included studies showed a propen-
sity for a shorter stay in both hospital and ICU, all studies that eval-
uated the clinical severity of the participant’s condition (Annane
2013; Liu 2013; Schroeder 2009; Svoboda 2007), reinfection
(Deliberato 2013; Nobre 2008; Oliveira 2013) and duration of
mechanical ventilation (Annane 2013; Shehabi 2014; Svoboda
2007) showed no relevant effect associated with procalcitonin-
guided antimicrobial therapy. However, the higher proportion of
reinfection among procalcitonin groups is supposed to be caused
by reduced antibiotic exposure.
Other outcomes of potential interest for the user
Investigators reported significant effects in favour of procal-
citonin-guided antimicrobial therapy for other outcomes not
planned for this systematic review, specifically, mortality at day
14 (Dharaniyadewi 2013) and empirical antibiotic initiation
(Dharaniyadewi 2013) and five additional ways of measuring
the time receiving antimicrobial treatment (Nobre 2008; Oliveira
2013; Shehabi 2014). More promising findings were the cost re-
ductions associated with procalcitonin-guided antimicrobial ther-
apy, which varied from 17% to 75%, depending on themethod of
cost evaluation applied (Deliberato 2013; Schroeder 2009). How-
ever, all of these results are limited and should be read with cau-
tion.
Overall completeness and applicability of
evidence
Evidence presented in this systematic review shows absence of a
clear effect of procalcitonin-guided antimicrobial therapy in min-
imizing mortality, reinfection, clinical severity or mechanical ven-
tilation of patients with sepsis, severe sepsis or septic shock. How-
ever, procalcitonin evaluation has relevant potential for reducing
the duration of antimicrobial therapy, as well as patient stay in
both hospital and ICU.
The reader should consider the possibility of insufficient sample
power for all outcomes because of the low number of included
studies, which totalled at most 1156 participants for one outcome
in primary studies: mortality at longest follow-up.Otherwise, a
post hoc sensitivity analysis performed to test the effects of in-
cluding three studies with inclusion criteria not specific for sepsis,
severe sepsis or septic shock (Bouadma 2010; Jensen 2011; Layios
2012) had no significant effect on measures of mortality.
It is important to consider that, although we found low mortality
rates of around 20% in both comparison groups, all studies had
included high percentages of participants with severe and/or septic
shock, with the exception ofHochreiter 2009 and Liu 2013, which
did not specify these proportions.
Although it was not previously planned as a primary or secondary
outcome, our analysis revealed promising effects of procalcitonin-
guided antimicrobial therapy in reducing costs as a probable con-
sequence of reducing time on the antimicrobial regimen, but such
findings should be confirmed/refuted by future experimental or
observational studies in which investigators perform economic
analysis.
Another important issue involves the diagnostic accuracy of pro-
calcitonin for septic conditions and their prognosis. Despite
its limitations, no better biomarker for sepsis and its progno-
sis is known (García de Guadiana-Romualdo 2015; Garnacho-
Montero 2014;Hoeboer 2015; Leli 2014; Liu 2015;Nargis 2014).
Quality of the evidence
According to Summary of findings for the main comparison, we
considered the evidence to be of lowquality formortality at longest
follow-up, mortality at 28 days and mortality at ICU discharge,
and of moderate quality for mortality at hospital discharge, with
no significant effect of procalcitonin-guided antimicrobial ther-
apy, even when this approach was compared with standard care.
Although we included 10 studies in this systematic review, only
the outcome of “mortality at longest follow-up” was reported by
10 studies, for which trial sequential analysis showed an actual
sample size corresponding to approximately 40% of the required
information size (1156 of 2853 participants). Moreover, although
four studies reported relevant reduction in the time of antimicro-
bial therapy, these studies were associated with serious risk of bias,
resulting in evidence of very low quality for this specific outcome.
Visual inspection of the funnel plot revealed no asymmetry, sug-
gesting absence of publication bias. The possibility that investiga-
tors have not made their studies available for reasons of absence of
effect is improbable because most of the studies included in this
systematic review showed absence of differences for several other
outcomes, including primary and secondary outcomes. Even so,
we should not dismiss the possibility that investigators may not
make available studies showing negative effects of procalcitonin-
guided antimicrobial therapy because studies with positive results
are more likely to be published (Kicinski 2013).
One of the most important points to be stressed to the reader and
the scientific community is that both the precision of our effect
estimates and the quality of the evidence were affected by the
large number of dependent variables that have been evaluated in
studies published to this point. In this systematic review, we could
find 59 outcomes in 10 studies. Thus, higher-quality evidence
will certainly be achieved if researchers concentrate their efforts
on analysis of common and clinically relevant outcomes. Upon
thinking of the large divergence of outcomes assessed in these
studies, we provided estimates of effects for all outcomes reported
in the primary studies included in this review.
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Potential biases in the review process
Besides using a highly sensitive strategy in our search for stud-
ies, we applied no language restrictions, resulting in the inclusion
of a publication written in Chinese (Liu 2013). After we reran
the search (October 2016), we retrieved three additional stud-
ies of interest and included them in the list of Studies awaiting
classification. We will incorporate these studies into our formal
review findings during the review update; these findings will con-
tribute 94.4% (2695 participants) of the required information size
of 2853 participants, according to the trial sequential analysis. Al-
though it is improbable that these studies will change estimated
effects on mortality, they may change other relevant outcomes,
especially hospital and ICU length of stay, as well as time on an-
timicrobial therapy and mechanical ventilation.
We could not minimize during the review process a source of bias
that was precisely related to the evaluation of risk of bias for some
studies because we had no success in obtaining additional infor-
mation from the authors of four primary studies (Dharaniyadewi
2013; Hochreiter 2009; Liu 2013; Schroeder 2009). One of these
studies is available only as an extended abstract (Dharaniyadewi
2013).
We included mortality at longest follow-up as one additional pri-
mary outcome because absence of evidence on mortality often re-
sults from insufficient power, as well as from clinical and method-
ological heterogeneity between studies. However, we believe such
an inclusion does not introduce potential bias into the review pro-
cess because no substitution of outcomes occurred, and evidence
of absence of effect could be reinforced by this new outcome.
Agreements and disagreements with other
studies or reviews
In a narrative review with some elements of a systematic review
(systematic search across relevant databases), Mann 2011 focused
analysis on the accuracy of procalcitonin for diagnosing sepsis in
critically ill burn patients. After analysing 14 observational studies
and five systematic reviews, these review authors supported the
discriminatory capacity of procalcitonin as an important tool to be
combined with the clinical diagnosis of sepsis. Another narrative
review by Schuetz 2013 not only supports procalcitonin evalua-
tion as a valuable diagnostic tool for respiratory infection and sep-
sis but also suggests desired repercussions of procalcitonin evalua-
tion in reducing the time it takes to receive antimicrobial therapy,
without affecting mortality. Besides narrative reviews, the medical
literature already includes several systematic reviews conducted to
investigate the potential causal relationship between procalcitonin
monitoring and relevant outcomes such as mortality, but these
review authors included studies that used different inclusion cri-
teria (Kopterides 2010; Prkno 2013; Schuetz 2011). These three
systematic reviews yielded a total of 14 included randomized con-
trolled trials (RCTs).
Two systematic reviews analysed studies consisting of critically ill
adult and neonatal participants (Kopterides 2010), as well as adult
participants from primary care, emergency department and ICU
(Schuetz 2011), but review authors were not strictly interested
in patients with sepsis, severe sepsis and/or septic shock at study
entry, according to our inclusion criteria. Another systematic re-
view by Prkno 2013 included RCTs and observational studies that
evaluated adult participants with severe sepsis. Among the RCTs
analysed by Prkno 2013, we noted the inclusion of Jensen 2011,
which we did not consider in our systematic review. We clearly
justified the exclusion of Jensen 2011 from our systematic review
on the basis of broad inclusion criteria for patients admitted to the
ICU, also without a strict interest in sepsis, severe sepsis or septic
shock, which was similar to the approach of Kopterides 2010 and
Schuetz 2011. Another difference from other systematic reviews
was our inclusion of three additional studies thatmet our inclusion
criteria (Liu 2013;Oliveira 2013; Shehabi 2014). Even under such
methodological divergences, Prkno 2013, Kopterides 2010 and
Schuetz 2011 provided conclusions consistent with those of our
systematic review because they noted the same general evidence of
absence of effect for mortality and shorter time receiving antibi-
otic treatment that we had observed in procalcitonin-guided an-
timicrobial therapy as compared with non-procalcitonin-guided
treatment. However, as opposed to Kopterides 2010 and Prkno
2013, our systematic review shows a probable reduction in the
time patients stay in the hospital and in the ICU, which remains
to be adequately proven.
Besides the above-mentioned general agreement among systematic
reviews, other updated and important observational and health
economic studies have reported shorter hospital stay (Kip 2015)
and less time receiving antibiotic therapy (Hohn 2013; Hohn
2015; Kip 2015; Maseda 2015), with a probable consequence of
relevant cost reductions, as reported specifically by Kip 2015.
Finally, it is important to consider that, since 2012, one of the
main existing guidelines for dealing with severe sepsis and septic
shock (Dellinger 2013) has included recommending procalcitonin
to support clinicians while they decide whether or not to discon-
tinue empirical antimicrobial therapy for patients with septic con-
ditions. However, Dellinger 2013 assumes low quality of available
evidence for this recommendation.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Evidence of low to moderate quality does not support the use of
procalcitonin-guided antimicrobial therapy tominimizemortality,
reinfection, clinical severity, mechanical ventilation, or duration
of antimicrobial therapy of patients with sepsis, severe sepsis or
septic shock. However, the reader should consider the possibility
of insufficient sample power for all outcomes.
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Implications for research
The findings of this systematic review suggest promising effects of
procalcitonin-guided antimicrobial therapy in reducing the stay
of patients in both the hospital and the ICU, which deserve better
confirmation from RCTs. Next trials should include an additional
1697 participants to confirm possible superiority of procalcitonin
for mortality at longest follow-up as compared with control. The
possible reduction in costs (as a probable consequence of reduced
time on the antimicrobial regimen) should also be confirmed/re-
futed by future studies in which investigators perform cost analy-
ses.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Annane 2013
Methods Study design : multi-centre, parallel, randomized, single-blind, controlled trial
Setting : 8 ICUs in France
Participants Inclusion criteria : all ICU patients with severe or septic shock presenting systemic
inflammatory response syndrome, acute dysfunction of at least 1 organ, absence of
indisputable clinical infection and negative microbial cultures, all of them for < 48 hours
Exclusion criteria : pregnancy, burns over ≥ 15% of body surface area, trauma, outpa-
tient or inpatient cardiac arrest, post-orthopaedic surgery status drug-related neutrope-
nia, withdrawal of life-supportive therapies or a decision to withhold them, indisputable
clinical infection or antibiotic exposure ≥ 48 hours during the time shortly before ICU
admission
Interventions Group 1 (N = 31): Both initiation and discontinuation of antibiotics were guided by a
PCT-based algorithm applied at 6 hours and on day 3 and day 5 post randomization.
Antibiotic therapy was not to be started or was to be halted when PCT was < 0.25 µg/
L, was strongly discouraged when PCT was ≥ 0.25 to < 0.5 µg/L, was recommended
when PCT was ≥ 0.5 to < 5 µg/L and was strongly recommended when PCT was ≥
5 µg/L. For participants enrolled in the 48-hour postoperative period, respective PCT
cut-offs were < 4 µg/L,≥ 4 to < 9 µg/L and≥ 9 µg/L. Investigators were strongly asked
not to over-rule the algorithm every day up to study day 5
Group 2 (N = 31): In the control arm, the decision to start or stop antibiotic therapy
was made at the discretion of the participant’s physician, without knowledge of the
participant’s PCT concentrations
Outcomes 1. Proportion of antibiotic-treated participants at 6 hours
2. Proportion of antibiotic-treated participants at day 3
3. Proportion of antibiotic-treated participants at day 5
4. Time on antibiotic therapy (median days and interquartile rates)
5. Participants who had started antibiotics at day 1 post randomization
6. Mortality at day 5 post randomization
7. ICU mortality
8. In-hospital mortality
9. Mortality at hospital discharge
10. SOFA score at day 3
11. SOFA score at day 5
12. ICU length of stay
13. Hospital length of stay
14. Non-survivors considered as being antibiotic-free
15. Non-survivors considered as being treated with antibiotic
16. All participants with last information carried over for non-survivors
17. Days on antibiotic therapy
18. Antibiotic therapy-free days
19. Days on mechanical ventilation
20. Acquired infections at day 3
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Annane 2013 (Continued)
21. Acquired infections at day 5
22. Acquired infections at day 3
23. Acquired infections at any time post randomization
24. Nasal swabs (methicillin-resistant Staphylococcus aureus)
25. Rectal swabs (extended-spectrum β-lactamase-resistant)
26. Rectal swabs (Enterobacter klebsiella)
Conflicts of interest and/or funding None detected
Notes Sample size : Study authors estimated that on day 5, 85% of control participants would
be taking antibiotics. Thus, they calculated that 57 participants in each arm would be
needed to detect in a 2-sided test with an 80% probability and a 0.05 type I error a 25%
absolute reduction in the proportion of antibiotic-treated participants on day 5. They
also estimated that 20% of participants would eventually be withdrawn from the study
after showing indisputable infection. Thus, 140 participants in total (70 in each arm)
would be needed
PCT measures : PCT levels were measured with the BRAHMS PCT-sensitive KRYP-
TOR assay
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomized in a 1:1 ra-
tio according to a computer-generated list
and were stratified by centre and according
to whether or not participants underwent
surgery in the past 48 hours, using permu-
tation blocks
Allocation concealment (selection bias) Low risk Randomization was centralized through a
secured website and was performed by an
independent statistician. The sizes of the
strata remained unknown to investigators
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Masking of antibiotic therapy was not fea-
sible in this study, but In the control arm,
participants, physicians, nurses, investiga-
tors, study co-ordinators, the statistician
and the sponsor remained blinded to PCT
levels throughout the study
Blinding of outcome assessment (detection
bias)
All outcomes
High risk In the control arm, participants, physi-
cians, nurses, investigators, study co-ordi-
nators, the statistician and the sponsor re-
mained blinded to PCT levels throughout
the study
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Annane 2013 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Although 6.45% (4/62) of all participants
withdrew after randomization (PCT, n = 1;
non-PCT, n = 3), study authors made avail-
able a clear flow of participants, permitting
both intention-to-treat and available case
analyses
Selective reporting (reporting bias) Low risk Clinically relevant outcomes were analysed
and were previously planned in the clini-
caltrials.gov study (NCT01025180)
Other bias Low risk None was suspected.
Deliberato 2013
Methods Study design : parallel-group, open-label, randomized controlled trial
Setting : ICU of a tertiary care, private hospital in São Paulo, Brazil. This open-model
ICU is a 38-bed medical-surgical unit where approximately 2200 patients are admitted
each year
Participants Inclusion criteria : patient with microbiologically confirmed infection (blood, urine,
tracheal aspirate or bronchoalveolar lavage fluid cultures) with sepsis, severe sepsis and
septic shock (ACCP/SCCM Consensus Conference Committee 1992 criteria). More
than 50% of patients had bloodstream infection
Exclusion criteria : (1) start of antibiotic therapy more than 48 hours before the date
when cultures were performed; (2) participants younger than 18 years of age; (3) known
pregnancy; (4) infection requiring prolonged antibiotic therapy, such as bacterial en-
docarditis, hepatic or brain abscess, deep abscess, mediastinitis and osteomyelitis; (5)
severe infection caused by viruses, parasites, fungi or mycobacteria; (6) chronic localized
infection, such as chronic osteomyelitis or chronic prostatitis; (7) patients without indi-
cation for ICU admission, as determined by the attending physician; and (8) negative
cultures (blood, urine, tracheal aspirate or bronchoalveolar lavage fluid) in participants
with suspected sepsis, severe sepsis or septic shock
Interventions Group 1 (N = 42): PCT group had PCT andCRP levelsmeasured at day 0 (bacteraemia)
, 5 or 7 (if positive blood culture), and then every 48 hours until hospital discharge or
death or until antibiotics were stopped. A predefined PCT protocol was used together
with the clinical outcome to guide the physician’s decision to discontinue antibiotics.
The PCT protocol encouraged the physician to discontinue the antibiotics when (1)
PCT dropped more than 90% from peak level or (2) an absolute value < 0.5 ng/mL
was reached. Investigators did not interfere with the duration of prescribed antibiotic
therapy
Group 2 (N = 39): standard care in which all participants received antibiotic therapy
based on the possible source of infection and the local susceptibility profile, as prescribed
by the attending physician. By our local hospital policy, participants in the ICU cannot
receive antibiotic therapy for longer than 14 days unless they have been specified as
needing a prolonged duration of antibiotic therapy as the standard of care. Investigators
did not interfere with the duration of prescribed antibiotic therapy
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Deliberato 2013 (Continued)
Outcomes 1. Duration of antibiotic therapy
2. In-hospital mortality
3. ICU mortality
4. ICU length of stay (days)
5. Recurrence of the initial infection
6. CRP levels
7. Costs: by using total costs of the antibiotic treatment used in both groups plus the
cost of PCT used in the PCT group divided by the number of participants in each
group (per protocol analysis)
Conflicts of interest and/or funding None was detected.
Notes Sample size : Study authors estimated that inclusion of 29 participants in each study
group would yield 90% power to detect a 40% reduction in exposure to the antibiotic,
with a 2-tailed test of significance set at 0.05
PCT measures : automated test - VIDAS®BRAHMS PCT from bioMérieux (Rhône,
France)
Questions to study authors
How do you define intention-to-treat analysis (ITT)?
How do you define per-protocol analysis?
Data showed 2 (4.8%) and 4 (10.3%) in-hospital mortalities by ITT analysis, respec-
tively, in PCT and non-PCT groups. How did you find these numbers? Did you receive
information from excluded participants ?
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Folders were randomly and blindly as-
signed as “PCT group” or “standard group”
Allocation concealment (selection bias) High risk 2 study authors randomly drew 1 folder
from a black box containing 100 folders
(50 “PCT group” and 50 “control group”)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk investigators were aware of assignments.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk investigators were aware of assignments.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcomes were previously planned in the
trial registered as NCT01494675. Study
authors made available a clear flow of par-
ticipants within the study. Additionally,
they offered both intention-to-treat and
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available case analyses
Selective reporting (reporting bias) Low risk Relevant outcomes were evaluated.
Other bias Low risk None was suspected.
Dharaniyadewi 2013
Methods Study design : parallel-group, randomized controlled trial
Setting : emergency department in internal medicine (Cipto Mangunkusomo Hospital,
Indonesia)
Participants Inclusion criteria : septic participants (with at least 2 concomitant systemic inflamma-
tory response syndrome criteria) older than 18 years with and without signs of organ
hypoperfusion or dysfunction
Exclusion criteria : not informed by study authors
Interventions Group 1 (N = 100): semiquantitative PCT-examined patients
Group 2 (N = 105): standard care: Semi-quantitative PCT test results will be informed
to physicians taking care of participants
Outcomes 1. 14-Day mortality
2. Empirical antibiotic initiation ≤ 6 hours
3. Empirical antibiotic initiation > 6 hours
4. Appropriateness of empirical antibiotics
5. 14-Day mortality
Conflicts of interest and/or funding None was detected.
Notes Sample size : not informed
PCT measures : not informed
A tropical infection consultant assessed the appropriateness of empirical antibiotics on
the basis of Pedoman Umum Penggunaan Antibiotik Departemen Kesehatan Republik
Indonesia
We had no success in contacting study authors.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information was provided by study au-
thors.
Allocation concealment (selection bias) Unclear risk No information was provided by study au-
thors.
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Dharaniyadewi 2013 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information was provided by study au-
thors.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information was provided by study au-
thors.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Study authors made clear the flow dia-
gram of participants within the study (per-
protocol analysis). Outcomes were previ-
ously planned in the trial registered as
NCT01862185
Selective reporting (reporting bias) High risk Relevant outcomes were evaluated.
Other bias High risk Study authors did not provide detailed
PCT algorithm for dealing with antimicro-
bial therapies
Hochreiter 2009
Methods Study design : parallel-group, randomized controlled trial
Setting : surgical intensive care ward at the West Coast Hospital Heide (Germany)
Participants Inclusion criteria : participants requiring antibiotic therapy on the basis of confirmed
or highly suspected bacterial infection and at least 2 concomitant SIRS criteria
Exclusion criteria : not informed by study authors
Interventions Group 1 (N = 57): PCT-guided antibiotic regimen based on confirmed or highly sus-
pected bacterial infection. Antibiotic therapywas discontinued if clinical signs and symp-
toms of infection improved and PCT decreased to less than 1 ng/mL, or if the PCT
value was greater than 1 ng/m: but had dropped to 25% to 35% of the initial value over
3 days. The physician in charge had the option to proceed with or adjust the antibiotic
treatment if he or she had clinical reasons to do so, at any time point
Group 2 (N = 53): standard antibiotic regimen also based on confirmed or highly
suspected bacterial infection. Antibiotic treatmentwas applied as standard regimen over 8
days. Also, the physician in charge had the option to proceed with or adjust the antibiotic
treatment if he or she had clinical reasons to do so, at any time point
Outcomes 1. Distribution of antibiotic classes
2. Duration of antibiotic treatment (days)
3. ICU length of stay (days)
4. SOFA score
5. Leucocyte count
6. IL-6 concentrations
7. CRP concentrations
8. PCT concentrations
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9. Mortality (until hospital discharge)
Conflicts of interest and/or funding SS has served as consultant and has received payments from BRAHMS AG for speaking
engagements
Notes Sample size : not informed
PCTmeasures : by BRAHMS PCT LIA® (BRAHMS Aktiengesellschaft, Hennigsdorf,
Germany)
We had no success in contacting study authors.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not informed
Allocation concealment (selection bias) High risk An open-label study as reported by study
authors
Blinding of participants and personnel
(performance bias)
All outcomes
High risk An open-label study as reported by study
authors
Blinding of outcome assessment (detection
bias)
All outcomes
High risk An open-label study as reported by study
authors
Incomplete outcome data (attrition bias)
All outcomes
Low risk Study authors made available a clear flow
of participants within the study (all partic-
ipants were analysed)
Selective reporting (reporting bias) Low risk Relevant outcomes were evaluated.
Other bias Low risk None was suspected.
Liu 2013
Methods Study design : parallel-group, randomized controlled trial
Setting : 1 University ICU (First Hospital of Jilin Universit, China)
Participants Inclusion criteria : participants aged ≥ 18 years with suspected bacterial sepsis, severe
sepsis and septic shock, according to ACCP/SCCM Consensus Conference Committee
1992) criteria
Exclusion criteria : bacterial culture results for Pseudomonas aeruginosa, Aeromonas,
Acinetobacter baumannii, Mycobacterium tuberculosis or fungal infection; suspected virus
or parasite infection; chronic localized infection; more than 48-hour antimicrobial drug
treatment; immunodeficiency (HIV, white blood disease); patients with cancer
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Interventions Group 1 (N = 42): Antibiotic therapy was guided by PCT results on a daily basis.
When no active symptoms of infection were shown; acute physiology and APACHE
scores declined; and PCT values decreased by more than 90% or PCT value was lower
than 0.25 µg/L - selected as drug withdrawal
Group 2 (N = 40): regular antimicrobial therapy
Outcomes 1. Time of antimicrobial drug (days)
2. Length of hospital stay (days)
3. ICU stay time (days)
4. Death in 28 days
5. Relapse in 28 days (not defined by study authors)
6. Clinical cure (not defined by study authors)
7. APACHE score
Conflicts of interest and/or funding None was detected.
Notes Sample size : No information was provided.
PCT measures:
Study authors followed-up discharged participants by telephone
We had no success in contacting study authors.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not informed
Allocation concealment (selection bias) Unclear risk Not informed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not informed
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not informed
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No clear information was available about
the flow of participants (all participants in-
formed in the study were analysed)
Selective reporting (reporting bias) Low risk Relevant outcomes were evaluated.
Other bias Low risk None was suspected.
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Nobre 2008
Methods Study design : parallel-group, open-label, randomized controlled trial
Setting : tertiary care, University Hospitals of Geneva (Switzerland)
Participants Inclusion criteria : all patients with suspected severe sepsis or septic shock admitted to
the ICU (32-bed, mixed medical and surgical adult patients, with 3200 admissions per
year). Patients developing severe sepsis or septic shock during their ICU stay were also
considered for enrolment. Study authors used Bone 1992 criteria
and reported 42% severe sepsis and 43% septic shock.
Exclusion criteria : (1) microbiologically documented infection caused by Pseudomonas
aeruginosa, Acinetobacter baumanni, Listeria spp.,Legionella pneumophila, Pneumocystis
jiroveci or Mycobacterium tuberculosis, for which a prolonged duration of antibiotic ther-
apy is standard of care (17); (2) severe infection due to viruses or parasites (e.g. haem-
orrhagic fever, malaria); (3) infectious condition requiring prolonged antibiotic therapy
(e.g. bacterial endocarditis, brain abscess, deep abscesses); (4) antibiotic therapy started
48 hours or longer before enrolment; (5) chronic localized infection (e.g. chronic os-
teomyelitis); (6) severely immunocompromised patients, such as those infected with
human immunodeficiency virus and with a CD4 count less than 200 cells/mm3, neu-
tropenic patients (500 neutrophils/mm3)or patients receiving immunosuppressive ther-
apy after solid organ transplantation; (7) withholding of life support; (8) absence of
antimicrobial treatment despite clinical suspicion of sepsis
Interventions Group 1 (N = 39): For participants with a favourable clinical course, investigators used
predefined “stopping rules” based on circulating PCT levels to encourage caregivers
to discontinue antibiotics. Participants with baseline PCT level greater than or equal
to 1 mg/L were reevaluated at day 5. Investigators encouraged treating physicians to
discontinue antibiotics when (1) PCTdropped bymore than 90% from the baseline peak
level, or (2) an absolute value below 0.25 mg/L was reached. Participants with PCT levels
below 1 mg/L at baseline were reevaluated at day 3; treating physicians were encouraged
to discontinue antibiotics when the PCT level was below 0.1 mg/L and careful clinical
evaluation ruled out severe infection. However, the final decision concerning antibiotic
therapy duration was always left to the discretion of the physician in charge
Group 2 (N = 40): standard practice, whereby participants received initial antibiotic
therapy based on local guidelines and susceptibility patterns, according to the decision
of the treating physician, who was unaware of the participant’s initial PCT levels; the
final decision concerning antibiotic therapy duration was always left to the discretion of
the physician in charge
Outcomes 1. Duration of antibiotic treatment (days), defined as antibiotic therapy given for the
first episode of infection for which the participant was included in the study
2. Incidence density of antibiotic exposure days, defined as a period of continuous
administration of a single antibiotic agent with no interruption for longer than 24
hours per 1000 inpatient days. This variable included all antibiotics administered for
longer than 24 hours during the study’s follow-up period (28 days).
3. Incidence rate ratio (IRR) of antibiotic exposure, calculated by the ratio of total
antibiotic exposure days between control group and PCT group participants .
4. Days alive without antibiotics, defined as a period of at least 24 hours without
antibiotic administration for a given participant, and comprising the entire follow-up
period (28 days, unless death or discharge occurred earlier)
5. 28-Day mortality in-hospital
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6. Length of stay in the ICU
7. Length of stay in the hospital
8. Clinical cure, defined as “clinical signs and symptoms present at baseline that had
resolved by the final clinical assessment”
9. Recurrence of the initial infection
10. Recurrence of the nosocomial superinfection (a frequent complication of drug
therapy for nosocomial infection, defined as if it became clinically apparent 48 hours
after admission and was not incubating at admission, and within 48 hours after ICU
discharge)
11. Sepsis-related mortality
12. Sepsis-unrelated mortality
Conflicts of interest and/or funding SH and JP received speaker honoraria from BRAHMS AG.
Notes Sample size : The trial was designed to enrol at least 66 participants, to obtain power of
90% to detect a 33% (4 day) difference in duration of antibiotic therapy for the initial
infection between the 2 groups based on an estimated baseline duration of 12 days. We
assumed a standard deviation (SD) of 5 days in both groups and an a error of 0.05
PCT measures: Kryptor-PCT (Brahms Diagnostica, Hennigsdorf, Germany)
Other notes :
• All participants included in the study had circulating PCT levels measured at
baseline and daily until the seventh day of follow-up (unless death or discharge
occurred earlier), or until antibiotics were stopped in participants randomized to the
PCT group. Thereafter, PCT was measured at 5-day intervals, even in those patients
transferred to the ward.
• Cases in which antibiotic treatment was continued despite the encouragement of
investigators to stop it were classified as “algorithm overruling.” Finally, participants
with positive blood cultures were ensured to receive at least 5 full days of parenteral
antibiotic therapy.
• Broad-spectrum parenteral antibiotics were prescribed for participants with
suspected severe sepsis or septic shock, depending on the suspected source of infection
and microbiological cultures, when available.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-based random number genera-
tion
Allocation concealment (selection bias) Low risk Allocation was issued by using opaque,
sealed, numbered envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label RCT
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Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label RCT
Incomplete outcome data (attrition bias)
All outcomes
Low risk Primary endpoints were first analysed on
the basis of an intention-to-treat analysis,
including all randomized participants. Ad-
ditionally, study authors made available a
clear flow of participants within the study
Selective reporting (reporting bias) Low risk Outcomes were previously planned in clin-
icaltrials.gov NCT 00250666. Relevant
outcomes were evaluated
Other bias Low risk None was suspected.
Oliveira 2013
Methods Study design : parallel-group, open-label, randomized controlled trial
Setting : 2 teaching ICUs (Brazil)
Participants Inclusion criteria : all adult patients 18 years of age or older with suspected severe sepsis
or septic shock (according to Bone 1992; Levy 2003 criteria).
Study authors reported 63% severe sepsis and 55.6% septic shock
Exclusion criteria: (1) confirmed microbiological infection by Pseudomonas aeruginosa,
Acinetobacter baumannii,Listeria species,Mycobacterium tuberculosis or fungi; (2) Staphy-
lococcus aureus bacteraemia; (3) suspected or confirmed severe infection caused by virus or
parasite; (4) infection that required long-term treatment, regardless of the etiologic agent
(e.g. bacterial endocarditis); (5) localized chronic infection (e.g. chronic osteomyelitis);
(6) more than 48 hours of antibiotic treatment; (7) immunosuppressed patients (such as
those diagnosed with HIV), patients with neutropenia (less than 500 neutrophils/mm
3), patients post solid organ transplant, patients receiving immunosuppressive therapy
and patients who received more than 1 mg/kg of prednisone or equivalent; (8) patients
under palliative care; (9) patients who suffered multiple trauma, burns or major surgery
in the previous 5 days; (10) patients given a diagnosis of pulmonary neoplasia, carcinoid
tumour or medullary tumour of the thyroid; and (11) patients who remained in the ICU
for no longer than 24 hours
Interventions Group 1 (N = 50): protocol based on serum PCT levels. Daily measurements, every
48 hours for 2 measurements in participants remaining in the ICU, then every 5 days.
The duration of antibiotic therapy was based on circulating PCT levels. Investigators
proposed interruption of antibiotics if a relative reduction of 90% in baseline PCT levels,
or if an absolute value lower than 0.1 ng/mL, was reached
Group 2 (N = 47): protocol based on serum CRP levels. Daily measurements, every
48 hours for 2 measurements in participants remaining in the ICU, then every 5 days.
The duration of antibiotic therapy was based on circulating CRP levels. Investigators
proposed interruption of antibiotics if a relative reduction of 50% in baseline CRP levels,
or if a value lower than 25 mg/dL, was reached
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Outcomes 1. Duration of antibiotic therapy for the first episode of infection, defined as the
period of antibiotic use for at least 24 hours during the 28 days of follow-up
2. Total number of days receiving antibiotic therapy
3. Days off antibiotic therapy, defined as a period of at least 24 hours without the
use of any antibiotics during 1000 live days of hospitalization
4. Death from any cause during the 28 days of follow-up in the hospital
5. Length of stay in the ICU
6. Length of stay in the hospital
7. Clinical cure, defined as the disappearance of signs and symptoms of infection
observed at inclusion in the study
8. Recurrent infection, defined as persistence of the pathogen originally causing the
infection
9. Nosocomial infection (courses of antimicrobial therapy administered at an
interval longer than 48 hours were considered directed to distinct infection episodes)
10. Protocol overruling
Participants were followed up for 28 days, or until death or hospital transference,
whichever came first
Conflicts of interest and/or funding Dr Nobre was paid for lectures by bioMérieux.
Notes Sample size : based on duration of antibiotic therapy in participants treated with a PCT-
guided protocol; would be at least 25% shorter than the duration observed in participants
treated according to a protocol based on serum CRP levels, resulting in 58 participants
per group - totalling 116 individuals (power of 80% and alpha error of 5%)
PCT measures: Vidas BRAHMS PCT (bioMérieux, Lyon, France)
CRP measures: Reactive test VITROS (Johnson & Johnson Clinical Diagnostics, Inc.,
Rochester, NY) was used to quantitatively measure the concentration of serum or plasma
CRP
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Table of random computer-generated
numbers. Sealed opaque envelopes were
used for randomization
Allocation concealment (selection bias) Low risk Sealed opaque envelopes were used for ran-
domization.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label RCT
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label RCT
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Study authorsmade available a clear flow of
participants within the study (per-protocol
analysis)
Selective reporting (reporting bias) Low risk Relevant outcomes were evaluated. Pro-
tocol was registered at ClinicalTrials.org
(NCT00934011)
Other bias Low risk None was suspected.
Schroeder 2009
Methods Study design : parallel-group, open-label, randomized controlled trial
Setting : ICU of the Department of Anesthesiology and Intensive Care Medicine at
Westküstenklinikum Heide (Germany)
Participants Inclusion criteria : patients after abdominal surgery and after the start of antibiotic
treatment with the diagnosis of severe sepsis (according to ACCP/SCCM Consensus
Conference Committee 1992 criteria)
Exclusion criteria : patients who did not meet the inclusion criteria, who refused in-
formed consent or who already had received antibiotic treatment before admission to
the ICU
Interventions Group 1 (n = 14): Antibiotic therapy was discontinued if clinical signs and symptoms
of sepsis improved and PCT values decreased to 1 ng/mL or less or dropped to 25%
to 35% of the initial PCT concentration over 3 consecutive days, but the physician in
charge was always free to decide whether to continue or change the antibiotic regimen
upon clinical judgement. Daily standard routine laboratory analysis including C-reactive
protein (CRP) was performed. Participants were also subjected to daily standard routine
laboratory analysis, including CRP
Group 2 (n = 13): Antibiotic treatment was discontinued according to clinical signs
and empirical rules, but the physician in charge was always free to decide whether to
continue or change the antibiotic regimen upon clinical judgement. Participants were
also subjected to daily standard routine laboratory analysis, including CRP, in the same
way as those in the PCT group
Outcomes 1. Length of hospital stay
2. Length of intensive care unit (ICU) stay (days)
3. Duration of antibiotic treatment (days)
4. PCT concentration
5. C-reactive protein (CRP) levels
6. Participants receiving the following antibiotic substances: acylaminopenicillin +
beta lactamase inhibitor; acylaminopenicillin + nitroimidazole and carbapenem
7. SOFAmax, defined as the “highest Sequential Organ Failure Assessment Score
during the study period”
8. Mortality until hospital discharge
Conflicts of interest and/or funding The corresponding author declared speaking engagements for BRAHMS AG
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Notes Sample size : Duration of antibiotic therapy for participants treated with a PCT-guided
protocol would be at least 25% shorter than the duration observed in participants treated
according to a protocol based on serumCRP levels, resulting in 58 participants per group
- totalling 116 individuals (power of 80% and alpha error of 5%)
PCTmeasures: BRAHMS PCT LIA® - B.R.A.H.M.S. Aktiengesellschaft, Hennigsdorf
(Germany)
We had no success in contacting study authors.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not informed
Allocation concealment (selection bias) Unclear risk Not informed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not informed
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not informed
Incomplete outcome data (attrition bias)
All outcomes
Low risk Study authors made available a clear flow
of participants within the study (all partic-
ipants were analysed)
Selective reporting (reporting bias) Low risk Relevant outcomes were evaluated.
Other bias Low risk None was suspected.
Shehabi 2014
Methods Study design : parallel-group, randomized controlled trial
Setting : 11 general academic and non-academic ICUs (Australia)
Participants Inclusion criteria : patients >18 years of age, admitted to ICUwithin previous 72 hours,
receiving parenteral and/or enteral antibiotics for a suspected bacterial infection (2) (with
2 or more systemic inflammatory response syndrome criteria) and expected to remain in
the ICU for longer than 24 hours
Exclusion criteria: patients receiving antibiotics for surgical prophylaxis or with proven
bacterial infection requiring more than 3 weeks of antibiotic therapy, with isolated sys-
temic fungal or systemic viral infection in the absence of bacterial infection, with neu-
tropenia with a neutrophil count less than 1000 cells/mm3, receiving immunosuppres-
sive agents, undergoing cardiac surgery or trauma or heat stroke within 48 hours, with
medullary thyroid or small cell lung cancer, not expected to survive to hospital discharge
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or with known pregnancy
Interventions Group 1 (N = 200): Clinicians could order additional PCT levels after day 7 at their
discretion. Daily PCT results were made available to the treating clinician. Antibiotics
were prescribed according to Australian Antibiotics Therapeutic Guidelines (24) and
antimicrobial stewardship (implemented by infectious diseases twice-weekly rounds and
on the basis of need consultations). Physicians were recommended to cease antibiotics
if initial or any subsequent PCT was negative at level < 0.10 ng/mL; if initial or any
subsequent PCT was borderline - level 0.10 to 0.25 ng/mL - and infection was highly
unlikely; or if subsequent PCT level declined by more than 90% from baseline. Inves-
tigators sought to assess antibiotic appropriateness and/or adequacy of source control if
PCT level at 48 hours was greater than 70% of baseline value
Group 2 (N = 200): standard care, with clinicians blinded to PCT levels; results were
faxed directly to the Clinical Informatics and Data Management Unit, Department of
Epidemiology and Preventive Medicine. Antibiotics were prescribed according to the
Australian Antibiotics Therapeutic Guidelines and antimicrobial stewardship (imple-
mented by infectious diseases twice-weekly rounds and on the basis of need consulta-
tions)
Outcomes 1. Antibiotic cessation at 28 days
2. Hospital discharge
3. Hospital mortality
4. Antibiotic-free days at day 28
5. Number of antibiotics daily defined doses (DDD) at day 28
6. ICU length of stay
7. Hospital length of stay
8. 90-Day all-cause mortality
9. Emergence of resistant micro-organisms
10. Number of algorithm violations
11. Readmission ICU reinfection
12. Isolates with multi-resistant organisms defined according to microbiological
sensitivity and minimum inhibitory concentration (MIC) to standard antibiotics
13. Therapy withdrawn in hospital
Conflicts of interest and/or funding Material support was provided by Roche Diagnostics, Thermo Fisher Scientific and
BioMérieux. Roche Diagnostics and Thermo Fisher Scientific provided additional un-
restricted grant funding
Notes Sample size : Study authors assumed a 25% (2.3 days) reduction in antibiotic treatment
from baseline of 9 days. To further account for potential dropout or loss to follow-up
(anticipated to be < 5%), a total of 400 participants were recruited (sample power of
90%)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Computer-generated randomization (via a
secured central study website) by block (1:
1 ratio) and stratified according to the pres-
ence of septic shock (defined by receipt
of inotrope and/or any vasopressors within
the previous 24 hours)
Allocation concealment (selection bias) Low risk Randomization via a secured central study
website
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Physicians who treated participants were
aware of the assignments
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Although datamanagementwas conducted
by a central bodywith a blinded statistician,
physicians who collected data were aware
of the assignments
Incomplete outcome data (attrition bias)
All outcomes
Low risk Study authorsmade available a clear flow of
participants within the study (per-protocol
analysis)
Selective reporting (reporting bias) Low risk Relevant outcomes were evaluated. Proto-
col was registered in the ANZRC 01111-
1117-1760 (ACTRN12610000809033)
Other bias Low risk None was suspected.
Svoboda 2007
Methods Study design : parallel-group, randomized controlled trial
Setting : 04 traumatological ICUs (Czech)
Participants Inclusion criteria : multiple trauma participants aged ≥ 18 years who developed sepsis
(according to Bone 1992 criteria).
Study authors reported septic shock in 71% and 68% in PCT vs non-PCT comparison
groups, respectively
Exclusion criteria : patients with chemical or burn trauma; with death perceived to be
imminent; or who had been designated as “not full support” or “do not resuscitate”
Interventions Group 1 (N=38): treatment decision according to PCT level. For severe sepsis with PCT
> 2 ng/mL and signalized bacteraemia, clinicians were motivated to change antibiotics
and catheters; participants with PCT ≤ 2 ng/mL and confirmed localized infection
were subjected to ultrasonography and/or CT, followed by repeated surgical treatment
(drainage, reoperation)
Group 2 (N = 34): standard evaluation of all parameters by consultant surgeon according
to treatment protocol of the health service. Standard supportive care, broad-spectrum
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Svoboda 2007 (Continued)
antibiotics and change of intravascular catheters were provided to all septic patients
according to evidence-base guidelines
Outcomes 1. Length of ICU stay
2. Days on mechanical ventilation
3. SOFA score until day 28
4. 28-Day mortality
5. PCT > 2 ng/mL, 5 days after randomization
6. Repeated surgery, 5 days after randomization
7. Time to resurgery, 5 days after randomization
8. CRP, 5 days after randomization
9. IL-6 (pg/mL), 5 days after randomization
10. TNF (pg/mL), 5 days after randomization
11. Antithrombin III, 5 days after randomization
Conflicts of interest and/or funding None was suspected.
Notes Sample size : not informed
PCT measures : PCT-Q, B.R.A.H.M.S., Hennigsdorf (Germany)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random number ta-
ble
Allocation concealment (selection bias) Low risk Study authors used opaque sealed num-
bered envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not informed
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not informed
Incomplete outcome data (attrition bias)
All outcomes
Low risk Study authors made available a clear flow
of participants within the study (all partic-
ipants were analysed)
Selective reporting (reporting bias) Low risk Relevant outcomes were evaluated.
Other bias Low risk None was suspected.
ACCP: American College of Chest Physicians.
APACHE: Acute Physiology and Chronic Health Evaluation.
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CD4: cluster of differentiation 4.
CRP: C-reactive protein.
DDD: daily defined doses.
HIV: human immunodeficiency virus.
ICU: intensive care unit.
IL: interleukin.
IRR: incidence rate ratio.
ITT: intention-to-treat analysis.
mg/dL: milligrams per decilitre.
MIC: minimum inhibitory concentration.
mL: millilitre.
N: total number of participants.
ng/mL: nanogram per millilitre.
PCT: procalcitonin.
pg/mL: picogram/ millilitre.
PO2: partial pressure of oxygen.
RCT: randomized controlled trial.
SCCM: Society of Critical Care Medicine.
SD: standard deviation.
SIRS: systemic inflammatory response syndrome.
SOFA: sequential organ failure assessment.
TNF: tumour necrosis factor.
µg/L: microgram per litre.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bodmann 2016 Retrospective study design
Bouadma 2010 RCT. Inclusion criteria not specific for sepsis, severe sepsis and/or septic shock (participants with suspected
bacterial infection, with no clear definition for diagnosis of sepsis)
Bréchot 2015 Economic analysis
Harrison 2015 Economic analysis
Jensen 2011 RCT with critically ill participants. Inclusion criteria not specific for sepsis, severe sepsis and/or septic shock
Kiehntopf 2011 Retrospective study design
Kip 2015 Economic evaluation
Kolici 2013 RCT in neonates
Kopterides 2010 Systematic review
Layios 2012 RCT. Inclusion criteria not specific for sepsis, severe sepsis and/or septic shock
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(Continued)
Lima 2016 RCT. Inclusion criteria strict for febrile neutropenia
Mann 2011 Systematic review
Pantelidou 2015 Narrative review
Prkno 2013 Systematic review
Sandifer 2012 Systematic review
Schuetz 2011 Systematic review
Schuetz 2013 Narrative review
Soni 2013 Systematic review
Stocker 2010a RCT in neonates
Stocker 2010b RCT in neonates
Ternhag 2010 Narrative review for chronic obstructive pulmonary disease
Westwood 2015 Economic evaluation
RCT: randomized controlled trial.
Characteristics of studies awaiting assessment [ordered by study ID]
Bloos 2016
Methods Study design : multi-centre, randomized, placebo-controlled trial
Setting : ICUs from 35 hospitals in Germany
Participants Inclusion criteria : severe sepsis/septic shock (ACCP/SCCM criteria), onset < 24 hours), ≥ 18 years of age
Exclusion criteria : pregnancy or breast-feeding, fertile female women not using contraceptive treatment, concomi-
tant participation in any study (last 30 days), previous participation in this trial, selenium intoxication, no compliance
with instructions of the study, imminent possibility of death due to coexisting disease(s), relationship of the partic-
ipant to one or more members of the study team, long-lasting duration of antimicrobial therapy due to infectious
diseases (i.e. endocarditis, tuberculosis, malaria, etc), immunocompromised participants
Interventions Group 1 (N = 552): PCT-based algorithm, both with and without sodium-selenite
Group 2 (N = 537): no PCT-based algorithm (antimicrobial therapy according to the discretion of the treating
physician), both with and without sodium-selenite
Sodium-selenite 1000 µg/d until the end of ICU treatment or for ≤ 21 days
PCT was measured at randomization and at days 4, 7, 10 and 14
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Bloos 2016 (Continued)
Outcomes 1. All-cause mortality (28 days)
2. All-cause mortality (90 days)
3. Mean total SOFA and SOFA subscores
4. Frequency and duration of mechanical ventilation (90 days)
5. Frequency and duration of vasopressor support
6. Frequency of adverse events and severe adverse events
7. Clinical cure and microbiological cure (days 4, 7, 10, 14)
8. Duration of antimicrobial therapy
9. Costs of antimicrobial therapy
10. Time to change of antibiotic therapy
11. Days alive without antimicrobial therapy
12. Frequency of resistances against antibiotics
13. ICU length of stay (90 days)
14. Hospital length of stay (90 days)
15. Rate of surgical procedures for focus control
16. Rate of procedures performed to diagnose infection
17. Frequency of new infections
Notes Sample size : not available
PCT measures : (BRAHMS, Germany; PCT-sensitive KRYPTOR Compact)
Financial support/funding : Kompetenznetz Sepsis, Biosyn, Brahms AG
de Jong 2016
Methods Study design : multi-centre, randomized, open-label, controlled trial
Setting : ICUs from 15 hospitals in the Netherlands.
Participants Inclusion criteria : > 18years, antibiotics initiated for suspected or proven infection on admission or during ICU
admission
Exclusion criteria : > 3weeks of prolonged antibiotic therapy for infectious clinical conditions such as endocarditis and
cerebral/hepatic abscess;severe infections due to viruses, parasites or tuberculosis; ICU admission for exclusive short-
term postoperative follow-up; anticipated length of stay < 24hours; cystic fibrosis; severely immunocompromised (e.
g. HIV and CD4 count < 200 cells/mm, neutropenic patients (< 500 neutrophils/mL)); solid organ transplantation;
moribund participants
Interventions Group 1 (N = 761): to discontinue antibiotics when procalcitonin concentration had decreased by at least 80% or
was ≤ 0·5 µg/L
Group 1 (N = 785): local antibiotic protocols
Outcomes 1. Mortality (28 days)
2. Mortality (1 year)
3. Consumption of antibiotics (defined daily dosage)
4. Time of antibiotic therapy (days)
5. Length of ICU stay
6. Costs of antibiotics (until 28 days in euros)
7. Costs of procalcitonin (until 28 days in euros)
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de Jong 2016 (Continued)
Notes Sample size : Study authors estimated 1816 participants, based on a mean baseline antibiotic duration of 8days, type
I error = 5%; type II error = 90% and drop-out rate of 20%
PCT measures : automated Kryptor platform (Thermo Fisher Scientific, Hennigsdorf, Germany), Roche Elecsys
Thermo Fisher Scientific PCT assay, Siemens Centaur Thermo Fisher Scientific PCT assay or BioMerieux Vidas
Thermo Fisher Scientific PCT assay
Financial support/funding : Thermo Fisher Scientific
Najafi 2015
Methods Study design : single-centre, randomized, single-blind, controlled trial
Setting : 1 ICU, Tehran
Participants Inclusion criteria : Patients with SIRS, according to at least 2 of the following criteria: body temperature > 38° C
or < 36° C, tachycardia > 90/min, tachypnoea > 20/min and leucocytosis > 12 × 109/L or a leftward shift with more
than 10% band cells or leukopenia < 4 × 109/L
Exclusion criteria : documented infection, pus from wound or abscess, empyema, thrombophlebitis, infection due
to virus or parasites, hypoxaemia (PO2 < 60 mmHg), oliguria (urine output < 30 mL/h), Glasgow Coma Scale score
of 3 without sedation, parenteral antibiotic usage (24 hours before admission to ICU), hospitalization (48 hours
before enrolment), conditions requiring prolonged antibiotic therapy (e.g. endocarditis, chronic localized infection
such as osteomyelitis), severely immunocompromised patients
Interventions Group 1 (N = 30): antibiotic treatment based on serum level of PCT (measured during 4-6 hours). PCT < 0.5 ng/mL
(no antimicrobial treatment, new measurement after 12 hours); PCT 0.5-2.0 ng/mL (no antimicrobial treatment,
new measurement after 8 hours); and PCT ≥ 2 ng/mL (antimicrobial treatment recommended)
Group 2 (N = 30): antibiotic empirical therapy
Outcomes 1. Total antibiotic exposure (days)
2. SOFA score on the first day
3. SOFA score on the second day
4. Clinical cure
5. In-hospital mortality
6. ICU stay
7. Hospital length of stay (days)
Notes Sample size : Study authors estimated 60 participants, based on 95% power to detect a 30% reduction in the use of
antibacterial agents
PCT measures : PCT levels were measured with time-resolved amplified cryptate emission (TRACE) assay
(BRAHMS, Germany; PCT-sensitive KRYPTOR Compact)
Financial support/funding : not reported
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D A T A A N D A N A L Y S E S
Comparison 1. PCT versus non-PCT (standard care or CRP: primary outcomes)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality at longest follow-up 10 1156 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.65, 1.01]
2 Mortality at 28 days 4 324 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.59, 1.28]
3 Mortality at ICU discharge 3 506 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.50, 2.11]
4 Mortality at hospital discharge 7 805 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.75, 1.27]
5 Time receiving antimicrobial
therapy (days) - mean (SD)
4 313 Mean Difference (IV, Random, 95% CI) -1.28 [-1.95, -0.61]
6 Time receiving antimicrobial
therapy (days) - median (IQR)
Other data No numeric data
Comparison 2. PCT versus non-PCT (standard care or CRP: secondary outcomes)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Hospital length of stay (days) -
median (IQR) or mean (SD)
Other data No numeric data
2 ICU length of stay (days) - mean
(SD)
4 291 Mean Difference (IV, Random, 95% CI) -2.05 [-3.14, -0.97]
3 ICU length of stay (days) -
median (IQR)
Other data No numeric data
4 SOFA score during ICU stay Other data No numeric data
5 SOFA score at day 3 Other data No numeric data
6 SOFA score at day 5 Other data No numeric data
7 SOFAmax score Other data No numeric data
8 APACHE II score Other data No numeric data
9 Reinfection (primary infection
relapse)
3 213 Risk Ratio (M-H, Random, 95% CI) 1.84 [0.43, 7.89]
10 Duration of mechanical
ventilation (days)
Other data No numeric data
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Comparison 3. PCT versus non-PCT - other outcomes of potential interest
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality at 5 days Other data No numeric data
2 Mortality at 14 days Other data No numeric data
3 Mortality at 90 days Other data No numeric data
4 Sepsis-related death* 2 488 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.50, 1.59]
5 Septic shock-related death Other data No numeric data
6 Patients on antibiotics at day 5
(last information carried over
for non-survivors)
Other data No numeric data
7 Patients on antibiotics at day 5
(non-survivors considered as
being treated with antibiotic)
Other data No numeric data
8 Patients on antibiotics at day 1
(among survivals)
Other data No numeric data
9 Patients on antibiotics at day 5
(survivors only)
Other data No numeric data
10 Therapy withdrawn in hospital Other data No numeric data
11 Appropriate empirical
antibiotics
Other data No numeric data
12 Empirical antibiotic initiation
≤ 6 hours
Other data No numeric data
13 Empirical antibiotic initiation
> 6 hours
Other data No numeric data
14 Infection at day 3 Other data No numeric data
15 Infection at day 5 Other data No numeric data
16 Infection at any time point
after randomization
Other data No numeric data
17 Nasal swabs positive
for methicillin-resistant
Staphylococcus aureus
Other data No numeric data
18 Rectal swabs positive
for extended-spectrum
β-lactamase-resistant
Other data No numeric data
19 Rectal swabs positive for
Enterobacter, Klebsiella
Other data No numeric data
20 Readmission due to secondary
infection
Other data No numeric data
21 Isolates with multi-resistant
organisms
Other data No numeric data
22 Nosocomial infection 2 162 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.77, 1.51]
23 Antibiotic therapy-free days
(mean, SD) - PCT vs standard
care
Other data No numeric data
24 Antibiotic therapy-free days
(median, IQR) - PCT vs
standard care
Other data No numeric data
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25 Antibiotic therapy-free days -
PCT vs CRP
Other data No numeric data
26 Duration of first episode of
antibiotic treatment (days)*
Other data No numeric data
27 Days of antibiotic exposure per
1000 inpatient days
Other data No numeric data
28 All antibiotics total daily
defined dose Irrespective of the
antimicrobial
Other data No numeric data
29 Antibiotics ”stopped earlier”
(hazard ratio)
Other data No numeric data
30 Antibiotics ”stopped earlier”
(hazard ratio) adjusted for
disease severity
Other data No numeric data
31 Time to antibiotic cessation at
day 28
Other data No numeric data
32 Duration of first episode of
antibiotic treatment (days)
Other data No numeric data
33 Antibiotic therapy-free
days according to different
subgroups
Other data No numeric data
33.1 Suspected sepsis Other data No numeric data
33.2 Suspected septic shock Other data No numeric data
33.3 Confirmed positive
culture
Other data No numeric data
33.4 Negative culture Other data No numeric data
33.5 Positive blood culture Other data No numeric data
33.6 Positive pulmonary
culture
Other data No numeric data
34 World Health Organization
daily defined dose per 100
occupied bed days
Other data No numeric data
35 Antibiotics maintained for 7
days because of bacteraemia
and/or a SOFA score above 10
at inclusion
Other data No numeric data
36 Antibiotic therapy
discontinuation in the first
episode of infection*
Other data No numeric data
37 Protocol overruling Other data No numeric data
38 Clinical cure* 3 244 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.90, 1.13]
39 Total costs with antibiotics per
comparison group (USD)
Other data No numeric data
40 Mean cost with antibiotics +
PCT kit per participant (USD)
Other data No numeric data
41 Cost reduction for antibiotic
treatment
Other data No numeric data
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Comparison 4. PCT versus non-PCT (standard care or CRP: ITT analysis)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality at longest follow-up
(imputing mortality for missing
participants)
10 1215 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.73, 1.32]
Analysis 1.1. Comparison 1 PCT versus non-PCT (standard care or CRP: primary outcomes), Outcome 1
Mortality at longest follow-up.
Review: Effectiveness and safety of procalcitonin evaluation for reducing mortality in adults with sepsis, severe sepsis or septic shock
Comparison: 1 PCT versus non-PCT (standard care or CRP: primary outcomes)
Outcome: 1 Mortality at longest follow-up
Study or subgroup Procalcitonin non-procalcitonin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Annane 2013 7/31 10/30 6.6 % 0.68 [ 0.30, 1.55 ]
Deliberato 2013 0/20 0/31 Not estimable
Dharaniyadewi 2013 26/95 53/102 25.7 % 0.53 [ 0.36, 0.77 ]
Hochreiter 2009 15/57 14/53 11.0 % 1.00 [ 0.53, 1.86 ]
Liu 2013 6/42 5/40 3.8 % 1.14 [ 0.38, 3.45 ]
Nobre 2008 6/31 7/37 4.8 % 1.02 [ 0.38, 2.73 ]
Oliveira 2013 21/49 21/45 19.4 % 0.92 [ 0.59, 1.44 ]
Schroeder 2009 3/14 3/13 2.4 % 0.93 [ 0.23, 3.81 ]
Shehabi 2014 30/196 26/198 17.0 % 1.17 [ 0.72, 1.90 ]
Svoboda 2007 10/38 13/34 9.4 % 0.69 [ 0.35, 1.36 ]
Total (95% CI) 573 583 100.0 % 0.81 [ 0.65, 1.01 ]
Total events: 124 (Procalcitonin), 152 (non-procalcitonin)
Heterogeneity: Tau2 = 0.01; Chi2 = 8.91, df = 8 (P = 0.35); I2 =10%
Test for overall effect: Z = 1.90 (P = 0.058)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours procalcitonin Favours non-procalcitonin
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Analysis 1.2. Comparison 1 PCT versus non-PCT (standard care or CRP: primary outcomes), Outcome 2
Mortality at 28 days.
Review: Effectiveness and safety of procalcitonin evaluation for reducing mortality in adults with sepsis, severe sepsis or septic shock
Comparison: 1 PCT versus non-PCT (standard care or CRP: primary outcomes)
Outcome: 2 Mortality at 28 days
Study or subgroup Procalcitonin non-procalcitonin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Liu 2013 6/42 5/40 12.0 % 1.14 [ 0.38, 3.45 ]
Nobre 2008 5/39 6/37 12.2 % 0.79 [ 0.26, 2.37 ]
Oliveira 2013 16/49 15/45 44.2 % 0.98 [ 0.55, 1.74 ]
Svoboda 2007 10/38 13/34 31.6 % 0.69 [ 0.35, 1.36 ]
Total (95% CI) 168 156 100.0 % 0.87 [ 0.59, 1.28 ]
Total events: 37 (Procalcitonin), 39 (non-procalcitonin)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.88, df = 3 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours procalcitonin Favours non-procalcitonin
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Analysis 1.3. Comparison 1 PCT versus non-PCT (standard care or CRP: primary outcomes), Outcome 3
Mortality at ICU discharge.
Review: Effectiveness and safety of procalcitonin evaluation for reducing mortality in adults with sepsis, severe sepsis or septic shock
Comparison: 1 PCT versus non-PCT (standard care or CRP: primary outcomes)
Outcome: 3 Mortality at ICU discharge
Study or subgroup Procalcitonin non-procalcitonin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Annane 2013 7/31 10/30 43.3 % 0.68 [ 0.30, 1.55 ]
Deliberato 2013 0/20 0/31 Not estimable
Shehabi 2014 21/196 15/198 56.7 % 1.41 [ 0.75, 2.66 ]
Total (95% CI) 247 259 100.0 % 1.03 [ 0.50, 2.11 ]
Total events: 28 (Procalcitonin), 25 (non-procalcitonin)
Heterogeneity: Tau2 = 0.13; Chi2 = 1.94, df = 1 (P = 0.16); I2 =49%
Test for overall effect: Z = 0.08 (P = 0.94)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours procalcitonin Favours non-procalcitonin
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Analysis 1.4. Comparison 1 PCT versus non-PCT (standard care or CRP: primary outcomes), Outcome 4
Mortality at hospital discharge.
Review: Effectiveness and safety of procalcitonin evaluation for reducing mortality in adults with sepsis, severe sepsis or septic shock
Comparison: 1 PCT versus non-PCT (standard care or CRP: primary outcomes)
Outcome: 4 Mortality at hospital discharge
Study or subgroup Procalcitonin Non-procalcitonin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Annane 2013 7/31 10/30 10.0 % 0.68 [ 0.30, 1.55 ]
Deliberato 2013 0/20 0/31 Not estimable
Hochreiter 2009 15/57 14/53 17.4 % 1.00 [ 0.53, 1.86 ]
Nobre 2008 6/31 7/37 7.1 % 1.02 [ 0.38, 2.73 ]
Oliveira 2013 21/49 21/45 33.6 % 0.92 [ 0.59, 1.44 ]
Schroeder 2009 3/14 3/13 3.4 % 0.93 [ 0.23, 3.81 ]
Shehabi 2014 30/196 26/198 28.6 % 1.17 [ 0.72, 1.90 ]
Total (95% CI) 398 407 100.0 % 0.98 [ 0.75, 1.27 ]
Total events: 82 (Procalcitonin), 81 (Non-procalcitonin)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.36, df = 5 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours procalcitonin Favours non-procalcitonin
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Analysis 1.5. Comparison 1 PCT versus non-PCT (standard care or CRP: primary outcomes), Outcome 5
Time receiving antimicrobial therapy (days) - mean (SD).
Review: Effectiveness and safety of procalcitonin evaluation for reducing mortality in adults with sepsis, severe sepsis or septic shock
Comparison: 1 PCT versus non-PCT (standard care or CRP: primary outcomes)
Outcome: 5 Time receiving antimicrobial therapy (days) - mean (SD)
Study or subgroup Procalcitonin non-procalcitonin
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Hochreiter 2009 57 5.9 (1.7) 53 7.9 (0.5) 29.0 % -2.00 [ -2.46, -1.54 ]
Liu 2013 42 8.1 (0.3) 40 9.3 (0.3) 33.2 % -1.20 [ -1.33, -1.07 ]
Oliveira 2013 49 8.1 (3.7) 45 7.2 (3.5) 13.0 % 0.90 [ -0.56, 2.36 ]
Schroeder 2009 14 6.6 (1.1) 13 8.3 (0.7) 24.8 % -1.70 [ -2.39, -1.01 ]
Total (95% CI) 162 151 100.0 % -1.28 [ -1.95, -0.61 ]
Heterogeneity: Tau2 = 0.35; Chi2 = 20.72, df = 3 (P = 0.00012); I2 =86%
Test for overall effect: Z = 3.76 (P = 0.00017)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours procalcitonin Favours non-procalcitonin
Analysis 1.6. Comparison 1 PCT versus non-PCT (standard care or CRP: primary outcomes), Outcome 6
Time receiving antimicrobial therapy (days) - median (IQR).
Time receiving antimicrobial therapy (days) - median (IQR)
Study Pro-
calcitonin, median
(range / interquar-
tile range [IQR])
non-Pro-
calcitonin, median
(range / interquar-
tile range [IQR])
Difference between
medians
P-value Favoured group
Annane 2013 5 (IQR: 2-5) 5 (IQR: 3-5) 0 days 0.52 Procalcionin
Deliberato 2013 9 (Range: 5-24) 13 (Range: 3-45) 4 days 0.008 Procalcionin
Oliveira 2013 13 (IQR: 7-18) 8 (IQR: 6-18) 5 days 0.183 non-Procalcionin
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Analysis 2.1. Comparison 2 PCT versus non-PCT (standard care or CRP: secondary outcomes), Outcome 1
Hospital length of stay (days) - median (IQR) or mean (SD).
Hospital length of stay (days) - median (IQR) or mean (SD)
Study Procalcitonin
median (Range
/ interquar-
tile range IQR)
or mean (SD)
non-
Procalcitonin
median (Range
/ interquar-
tile range IQR)
or mean (SD)
Meandifference Diference be-
tween medians
P-value Favoured group
Annane 2013 27 (IQR: 9-49) 33.0 (IQR: 11-
69)
not informed 6 days 0.22 procalcitonin
Deliberato 2013 10.5 (Range: 5-
547)
14.0 (Range: 2-
82)
not informed 3.5 days 0.34 procalcitonin
Liu 2013 27 (4.9 SD) 32 (5.4 SD) 5 days not applied <0.0001 (Z-test) procalcitonin
Nobre 2008 14.0 (Range: 5-
64)
21.0 (Range: 5-
89)
not informed 7 days 0.16 procalcitonin
Oliveira 2013 36 (IQR: 20-59) 25 (IQR: 13-52) not informed 11 days 0.175 non-
procalcitonin
Shehabi 2014 15 (IQR: 9-29) 17 (IQR: 10-32) not informed 2 days 0.19 procalcitonin
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Analysis 2.2. Comparison 2 PCT versus non-PCT (standard care or CRP: secondary outcomes), Outcome 2
ICU length of stay (days) - mean (SD).
Review: Effectiveness and safety of procalcitonin evaluation for reducing mortality in adults with sepsis, severe sepsis or septic shock
Comparison: 2 PCT versus non-PCT (standard care or CRP: secondary outcomes)
Outcome: 2 ICU length of stay (days) - mean (SD)
Study or subgroup Procalcitonin non-procalcitonin
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Hochreiter 2009 57 15.5 (12.5) 53 17.7 (10.1) 6.6 % -2.20 [ -6.43, 2.03 ]
Liu 2013 42 12 (2.9) 40 14 (2.7) 80.6 % -2.00 [ -3.21, -0.79 ]
Schroeder 2009 14 16.4 (8.3) 13 16.7 (5.6) 4.2 % -0.30 [ -5.61, 5.01 ]
Svoboda 2007 38 16.1 (6.9) 34 19.4 (8.9) 8.6 % -3.30 [ -7.01, 0.41 ]
Total (95% CI) 151 140 100.0 % -2.05 [ -3.14, -0.97 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.87, df = 3 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 3.70 (P = 0.00022)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
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Analysis 2.3. Comparison 2 PCT versus non-PCT (standard care or CRP: secondary outcomes), Outcome 3
ICU length of stay (days) - median (IQR).
ICU length of stay (days) - median (IQR)
Study Pro-
calcitonin, median
(range / interquar-
tile range [IQR])
non-Pro-
calcitonin, median
(range / interquar-
tile range [IQR])
Diference between
medians
P-value Favoured group
Annane 2013 22 (IQR: 8-42) 23 (IQR: 10-60) 1 day 0.58 Procalcitonin
Deliberato 2013 3.5 (Range: 1-57) 4 (Range: 1-28) 0.5 days 0.80 Procalcitonin
Nobre 2008 3 (Range: 1-18) 5 (Range: 1-30) 2 days 0.03 Procalcitonin
Oliveira 2013 14 (IQR: 9-24) 12 (IQR: 7-18) 2 days 0.164 non-Procalcitonin
Shehabi 2014 6 (IQR: 3-9.5) 6 (IQR: 4-10) 0 days 0.87 Procalcitonin
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Analysis 2.4. Comparison 2 PCT versus non-PCT (standard care or CRP: secondary outcomes), Outcome 4
SOFA score during ICU stay.
SOFA score during ICU stay
Study Procalcitonin,
Mean (SD)
(N = 38)
non-Procalcitonin,
Mean (SD)
(N = 34)
Mean difference
(95% CI)
P-value Favoured group
Svoboda 2007 7.9 (2.8) 9.3 (3.3) -1.40 [-2.82, 0.02] 0.05 Procalcitonin
Analysis 2.5. Comparison 2 PCT versus non-PCT (standard care or CRP: secondary outcomes), Outcome 5
SOFA score at day 3.
SOFA score at day 3
Study Procalcitonin, median (interquar-
tile range [IQR])
non-Procalcitonin, median (in-
terquartile range [IQR])
P-value
Annane 2013 8 (5-10) 8 (7-11) 0.85
Analysis 2.6. Comparison 2 PCT versus non-PCT (standard care or CRP: secondary outcomes), Outcome 6
SOFA score at day 5.
SOFA score at day 5
Study Procalcitonin, median (interquar-
tile range [IQR])
non-Procalcitonin, median (in-
terquartile range [IQR])
P-value
Annane 2013 8 (5-9) 8 (7-11) 0.61
Analysis 2.7. Comparison 2 PCT versus non-PCT (standard care or CRP: secondary outcomes), Outcome 7
SOFAmax score.
SOFAmax score
Study Procalcitonin,
Mean (95% CI)
(N = 14)
non-Procalcitonin,
Mean (95% CI)
(N = 13)
Mean difference
(95% cI)
P-value Favoured group
Schroeder 2009 7.3 (3.5) 8.4 (4.2) -1.00 (-3.93, 1.93) 0.50 Procalcitonin
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Analysis 2.8. Comparison 2 PCT versus non-PCT (standard care or CRP: secondary outcomes), Outcome 8
APACHE II score.
APACHE II score
Study Procalcsditonin,
Mean (SD)
(N = 42)
non-Procalcitonin,
Mean (SD)
(N = 40)
Mean difference
(95% cI)
P-value Favoured group
Liu 2013 5.7 (0.9) 6.2 (1.3) 0.50 (3.54, 4.54) 0.81 non-procalcitonin
Analysis 2.9. Comparison 2 PCT versus non-PCT (standard care or CRP: secondary outcomes), Outcome 9
Reinfection (primary infection relapse).
Review: Effectiveness and safety of procalcitonin evaluation for reducing mortality in adults with sepsis, severe sepsis or septic shock
Comparison: 2 PCT versus non-PCT (standard care or CRP: secondary outcomes)
Outcome: 9 Reinfection (primary infection relapse)
Study or subgroup Procalcitonin non-procalcitonin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Deliberato 2013 1/20 1/31 28.8 % 1.55 [ 0.10, 23.39 ]
Nobre 2008 1/31 1/37 28.4 % 1.19 [ 0.08, 18.31 ]
Oliveira 2013 3/49 1/45 42.8 % 2.76 [ 0.30, 25.54 ]
Total (95% CI) 100 113 100.0 % 1.84 [ 0.43, 7.89 ]
Total events: 5 (Procalcitonin), 3 (non-procalcitonin)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.24, df = 2 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.82 (P = 0.41)
Test for subgroup differences: Not applicable
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Analysis 2.10. Comparison 2 PCT versus non-PCT (standard care or CRP: secondary outcomes), Outcome
10 Duration of mechanical ventilation (days).
Duration of mechanical ventilation (days)
Study Procalcitonin, me-
dian (interquartile
range [IQR]) or
mean (SD)
non-Procalcitonin,
median (interquar-
tile range [IQR])
or mean (SD)
Difference between
medians
or
Difference between
means (95% CI)
P-value Favoured group
Annane 2013 11 (IQR: 5-25) 14 (IQR: 8-25) 3 days 0.56 procalcitonin
Shehabi 2014 4 (IQR: 2-9) 4 (IQR: 2-11) 0 days 0.99 procalcitonin
Svoboda 2007 10.3 (7.8 SD) 13.9 (9.4 SD) 3.6 days (0.42, 7.62) 0.08 procalcitonin
Analysis 3.1. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 1
Mortality at 5 days.
Mortality at 5 days
Study Procalcitonin (n/N) non-Procalcitonin
(n/N)
OR (95% CI) P-value Favoured group
Annane 2013 3/31 3/31 1.00 (0.22, 4.58) 1.0 no group
Analysis 3.2. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 2
Mortality at 14 days.
Mortality at 14 days
Study Procalcitonin (n/
N)
non-Procalcitonin
(n/N)
RR (95% CI) P-value Favoured group
Dharaniyadewi
2013
26/95 53/102 0.53 (0.36, 0.77) 0.00086 Procalcitonin
Analysis 3.3. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 3
Mortality at 90 days.
Mortality at 90 days
Study Procalcitonin (n/N) non-Procalcitonin
(n/N)
RR (95% CI) P-value Favoured group
Shehabi 2014 36/196 31/198 1.14 (0.73, 1.77) 0.56 non-Procalcitonin
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Analysis 3.4. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 4 Sepsis-
related death*.
Review: Effectiveness and safety of procalcitonin evaluation for reducing mortality in adults with sepsis, severe sepsis or septic shock
Comparison: 3 PCT versus non-PCT - other outcomes of potential interest
Outcome: 4 Sepsis-related death*
Study or subgroup Procalcitonin Non-procalcitonin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Oliveira 2013 6/49 6/45 29.9 % 0.92 [ 0.32, 2.64 ]
Shehabi 2014 14/196 16/198 70.1 % 0.88 [ 0.44, 1.76 ]
Total (95% CI) 245 243 100.0 % 0.89 [ 0.50, 1.59 ]
Total events: 20 (Procalcitonin), 22 (Non-procalcitonin)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.38 (P = 0.70)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours procalcitonin Favours non-procalcitonin
Analysis 3.5. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 5 Septic
shock-related death.
Septic shock-related death
Study Procalcitonin (n/N) non-Procalcitonin
(n/N)
OR (95% CI) P-value Favoured group
Shehabi 2014 14/196 16/198 0.88 (0.44, 1.76) 0.73 non-Procalcitonin
Analysis 3.6. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 6
Patients on antibiotics at day 5 (last information carried over for non-survivors).
Patients on antibiotics at day 5 (last information carried over for non-survivors)
Study Procalcitonin (n/N) non-Procalcitonin
(n/N)
OR (95% CI) P-value Favoured group
Annane 2013 18/30 22/28 0.76 (0.54, 1.08) 0.13 Procalcitonin
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Analysis 3.7. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 7
Patients on antibiotics at day 5 (non-survivors considered as being treated with antibiotic).
Patients on antibiotics at day 5 (non-survivors considered as being treated with antibiotic)
Study Procalcitonin (n/N) non-Procalcitonin
(n/N)
OR (95% CI) P-value Favoured group
Annane 2013 21/30 23/28 0.85 (0.64, 1.14) 0.28 Procalcitonin
Analysis 3.8. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 8
Patients on antibiotics at day 1 (among survivals).
Patients on antibiotics at day 1 (among survivals)
Study Procalcitonin (n/N) non-Procalcitonin
(n/N)
OR (95% CI) P-value Favoured group
Annane 2013 4/27 4/26 0.96 (0.27, 3.45) 0.95 Procalcitonin
Analysis 3.9. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 9
Patients on antibiotics at day 5 (survivors only).
Patients on antibiotics at day 5 (survivors only)
Study Procalcitonin (n/N) non-Procalcitonin
(n/N)
OR (95% CI) P-value Favoured group
Annane 2013 18/27 21/26 0.83 (0.60, 1.14) 0.25 Procalcitonin
Analysis 3.10. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 10
Therapy withdrawn in hospital.
Therapy withdrawn in hospital
Study Procalcitonin (n/N) non-Procalcitonin
(n/N)
OR (95% CI) P-value Favoured group
Shehabi 2014 38/196 35/198 1.10 (0.72, 1.66) 0.66 non-Procalcitonin
Analysis 3.11. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 11
Appropriate empirical antibiotics.
Appropriate empirical antibiotics
Study Procalcitonin (n/
N)
non-Procalcitonin
(n/N)
OR (95% CI) P-value Favoured group
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Appropriate empirical antibiotics (Continued)
Dharaniyadewi
2013
95/102 88/95 1.01 (0.93, 1.09) 0.89 non-Procalcitonin
Analysis 3.12. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 12
Empirical antibiotic initiation ≤ 6 hours.
Empirical antibiotic initiation ≤ 6 hours
Study Procalcitonin (n/
N)
non-Procalcitonin
(n/N)
OR (95% CI) P-value Favoured group
Dharaniyadewi
2013
83/95 36/102 2.48 (1.88, 3.25) <0.00001 Procalcitonin
Analysis 3.13. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 13
Empirical antibiotic initiation > 6 hours.
Empirical antibiotic initiation > 6 hours
Study Procalcitonin (n/
N)
non-Procalcitonin
(n/N)
OR (95% CI) P-value Favoured group
Dharaniyadewi
2013
12/95 66/102 0.20 (0.11, 0.34) <0.00001 Procalcitonin
Analysis 3.14. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 14
Infection at day 3.
Infection at day 3
Study Procalcitonin (n/N) non-Procalcitonin
(n/N)
OR (95% CI) P-value Favoured group
Annane 2013 1/18 1/19 1.06 (0.07, 15.64) 0.97 non-Procalcitonin
Analysis 3.15. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 15
Infection at day 5.
Infection at day 5
Study Procalcitonin (n/N) non-Procalcitonin
(n/N)
OR (95% CI) P-value Favoured group
Annane 2013 1/18 2/19 0.53 (0.05, 5.33) 0.59 Procalcitonin
68Effectiveness and safety of procalcitonin evaluation for reducing mortality in adults with sepsis, severe sepsis or septic shock (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.16. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 16
Infection at any time point after randomization.
Infection at any time point after randomization
Study Procalcitonin (n/N) non-Procalcitonin
(n/N)
OR (95% CI) P-value Favoured group
Annane 2013 2/18 3/19 0.70 (0.13, 3.73) 0.68 Procalcitonin
Analysis 3.17. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 17
Nasal swabs positive for methicillin-resistant Staphylococcus aureus.
Nasal swabs positive for methicillin-resistant Staphylococcus aureus
Study Procalcitonin (n/N) non-Procalcitonin
(n/N)
OR (95% CI) P-value Favoured group
Annane 2013 1/28 2/25 0.45 (0.04, 4.63) 0.50 Procalcitonin
Analysis 3.18. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 18
Rectal swabs positive for extended-spectrum β-lactamase-resistant.
Rectal swabs positive for extended-spectrum β-lactamase-resistant
Study Procalcitonin (n/N) non-Procalcitonin
(n/N)
OR (95% CI) P-value Favoured group
Annane 2013 1/25 0/22 2.65 (0.11, 62.00) 0.50 non-Procalcitonin
Analysis 3.19. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 19
Rectal swabs positive for Enterobacter, Klebsiella.
Rectal swabs positive for Enterobacter, Klebsiella
Study Procalcitonin (n/N) non-Procalcitonin
(n/N)
OR (95% CI) P-value Favoured group
Annane 2013 0/24 0/24 Not estimable Not estimable no group
Analysis 3.20. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 20
Readmission due to secondary infection.
Readmission due to secondary infection
Study Procalcitonin (n/N) non-Procalcitonin
(n/N)
OR (95% CI) P-value Favoured group
Shehabi 2014 6/174 12/183 0.53 [0.20, 1.37] 0.19 Procalcitonin
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Analysis 3.21. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 21
Isolates with multi-resistant organisms.
Isolates with multi-resistant organisms
Study Procalcitonin (n/N) non-Procalcitonin
(n/N)
OR (95% CI) P-value Favoured group
Shehabi 2014 45/324 43/355 1.54 (1.00, 2.36) 0.05 non-Procalcitonin
Analysis 3.22. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 22
Nosocomial infection.
Review: Effectiveness and safety of procalcitonin evaluation for reducing mortality in adults with sepsis, severe sepsis or septic shock
Comparison: 3 PCT versus non-PCT - other outcomes of potential interest
Outcome: 22 Nosocomial infection
Study or subgroup Procalcitonin Non-procalcitonin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Nobre 2008 7/31 11/37 16.8 % 0.76 [ 0.33, 1.72 ]
Oliveira 2013 29/49 23/45 83.2 % 1.16 [ 0.80, 1.67 ]
Total (95% CI) 80 82 100.0 % 1.08 [ 0.77, 1.51 ]
Total events: 36 (Procalcitonin), 34 (Non-procalcitonin)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.89, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 0.44 (P = 0.66)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours procalcitonin Favours non-procalcitonin
Analysis 3.23. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 23
Antibiotic therapy-free days (mean, SD) - PCT vs standard care.
Antibiotic therapy-free days (mean, SD) - PCT vs standard care
Study Procalcitonin
Mean (SD), N = 31
non-Procalcitonin
Mean (SD), N = 37
Meand difference
(95% CI)
P-value Favoured group
Nobre 2008 17.4 (7.6) 13.6 (7.6) 3.80 (0.17, 7.43) 0.04 Procalcitonin
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Analysis 3.24. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 24
Antibiotic therapy-free days (median, IQR) - PCT vs standard care.
Antibiotic therapy-free days (median, IQR) - PCT vs standard care
Study Procalci-
tonin, median (interquar-
tile range [IQR])
non-Procalci-
tonin, median (interquar-
tile range [IQR])
P-value Favoued group
Annane 2013 0 (0-3) 0 (0-2) not available Procalcitonin
Shehabi 2014 20 (11-22) 17 (7-22) 0.18 Procalcitonin
Analysis 3.25. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 25
Antibiotic therapy-free days - PCT vs CRP.
Antibiotic therapy-free days - PCT vs CRP
Study Procalcitonin, median/1,000 live
days (interquartile range [IQR])
C-Reactive Protein, median/
1,000 live days (interquartile range
[IQR])
P-value
Oliveira 2013 357.1 (0-541) 357.14 (33.3-509.2) 0.998
Analysis 3.26. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 26
Duration of first episode of antibiotic treatment (days)*.
Duration of first episode of antibiotic treatment (days)*
Study Procalcitonin
Mean (SD), N = 49
non-Procalcitonin
Mean (SD), N = 45
Mean difference
(95% CI)
P-value Favoured group
Oliveira 2013 8.1 (3.7) 7.2 (3.5) 0.90 (-0.56, 2.36) 0.23 Procalcitonin
Analysis 3.27. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 27
Days of antibiotic exposure per 1000 inpatient days.
Days of antibiotic exposure per 1000 inpatient days
Study Log [risk ratio] Standard error RR (95% CI) P-value Favoured group
Oliveira 2013 -0.079 0.059 0.92 (0.82, 1.04) 0.18 Procalcitonin
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Analysis 3.28. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 28 All
antibiotics total daily defined dose Irrespective of the antimicrobial.
All antibiotics total daily defined dose Irrespective of the antimicrobial
Study Procalci-
tonin, median (interquar-
tile range [IQR])
non-Procalci-
tonin, median (interquar-
tile range [IQR])
P-value Favoured group
Shehabi 2014 1200 (500-3000) 1500 (750-4000) 0.001 Procalcitonin
Analysis 3.29. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 29
Antibiotics “stopped earlier” (hazard ratio).
Antibiotics “stopped earlier” (hazard ratio)
Study Procalcitonin versus non-procalci-
tonin, hazard ratio (95% CI)
P-value Favoured group
Nobre 2008 1.9 (1.2-3.1) 0.009 Procalcitonin
Analysis 3.30. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 30
Antibiotics “stopped earlier” (hazard ratio) adjusted for disease severity.
Antibiotics “stopped earlier” (hazard ratio) adjusted for disease severity
Study Procalcitonin versus non-procalci-
tonin, hazard ratio (95% CI)
P-value Favoured group
Nobre 2008 1.9 (1.2-3.2) 0.009 Procalcitonin
Analysis 3.31. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 31
Time to antibiotic cessation at day 28.
Time to antibiotic cessation at day 28
Study Pro-
calcitonin Median,
median (interquar-
tile range [IQR])
(n = 196)
non-procalcitonin,
median (interquar-
tile range [IQR])
(n = 198)
Hazard-ratio (95%
CI)
P Favoured group
Shehabi 2014 9 [6-20] 11 [6-22] 1.06 (0.85-1.33) 0.59 Procalcitonin
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Analysis 3.32. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 32
Duration of first episode of antibiotic treatment (days).
Duration of first episode of antibiotic treatment (days)
Study Procalcitonin, me-
dian (range)
Non-procalcitonin,
median (range)
mean difference
(95% CI)
P-value Favoured group
Nobre 2008 6 (4-16) 10 (3-33) 3.2 (1.1 to 5.4) 0.003 non-Procalcitonin
Oliveira 2013 7 (6.0-8.5) 6 (5.0-7.0) not informed 0.06 procalcitonin
Analysis 3.33. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 33
Antibiotic therapy-free days according to different subgroups.
Antibiotic therapy-free days according to different subgroups
Study Procalci-
tonin, median (interquar-
tile range [IQR])
non-Procalci-
tonin, median (interquar-
tile range [IQR])
P-value Favoured group
Suspected sepsis Suspected sepsis
Shehabi 2014 9 (6-17) 11 (6-18) 0.74 non-procalcitonin
Suspected septic shock Suspected septic
Shehabi 2014 9 (6-22) 11 (6-24) 0.64 no-procalcitonin
Confirmed positive culture Confirmed positiv
Shehabi 2014 13 (7-27) 13 (8-26) 0.77 none
Negative culture Negative culture
Shehabi 2014 8 (4-12) 7 (4-15) 0.94 procalcitonin
Positive blood culture Positive blood cultur
Shehabi 2014 14 (8-23) 15 (7-27) 0.39 non-procalcitonin
Positive pulmonary culture Positive pulmonar
Shehabi 2014 11 (7-27) 15 (8-27) 0.33 non-procalcitonin
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Analysis 3.34. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 34
World Health Organization daily defined dose per 100 occupied bed days.
World Health Organization daily defined dose per 100 occupied bed days
Study Procalcitonin
Mean (SD)
(N = 196)
non-procalcitonin
Mean (SD)
(N = 198)
Mean difference
(95% CI)
P-value Favoured group
Shehabi 2014 135 (93) 139 (98) -4.00 (-22.86, 14.86) 0.68 Procalcitonin
Analysis 3.35. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 35
Antibiotics maintained for 7 days because of bacteraemia and/or a SOFA score above 10 at inclusion.
Antibiotics maintained for 7 days because of bacteraemia and/or a SOFA score above 10 at inclusion
Study Procalcitonin (n/N) non-Procalcitonin
(n/N)
RR (95% CI) P-value Favoured group
Oliveira 2013 17/49 8/45 1.95 (0.93, 4.08) 0.08 non-Procalcitonin
Analysis 3.36. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 36
Antibiotic therapy discontinuation in the first episode of infection*.
Antibiotic therapy discontinuation in the first episode of infection*
Study Hazard ratio (95% CI) P-value Favoured group
Oliveira 2013 1.206 (0.774-1.3) 0.1 C-reactive protein
Analysis 3.37. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 37
Protocol overruling.
Protocol overruling
Study Procalcitonin (n/N) non-Procalcitonin
(n/N)
RR (95% CI) P-value Favoured group
Oliveira 2013 6/49 7/45 0.79 (0.29, 2.17) 0.64 Procalcitonin
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Analysis 3.38. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 38
Clinical cure*.
Review: Effectiveness and safety of procalcitonin evaluation for reducing mortality in adults with sepsis, severe sepsis or septic shock
Comparison: 3 PCT versus non-PCT - other outcomes of potential interest
Outcome: 38 Clinical cure*
Study or subgroup Procalcitonin Non-procalcitonin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Liu 2013 33/42 34/40 30.0 % 0.92 [ 0.75, 1.13 ]
Nobre 2008 28/31 31/37 37.7 % 1.08 [ 0.90, 1.29 ]
Oliveira 2013 40/49 36/45 32.3 % 1.02 [ 0.84, 1.24 ]
Total (95% CI) 122 122 100.0 % 1.01 [ 0.90, 1.13 ]
Total events: 101 (Procalcitonin), 101 (Non-procalcitonin)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.24, df = 2 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.20 (P = 0.84)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours non-procalcitonin Favours procalcitonin
Analysis 3.39. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 39
Total costs with antibiotics per comparison group (USD).
Total costs with antibiotics per comparison group (USD)
Study Procalcitonin non-procalcitonin Between-group
absolute difference
P-value Favoured group
Deliberato 2013 US$ 10 608.00 US$ 42 397.00 US$ 31 789.00 not available procalcitonin
Analysis 3.40. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 40
Mean cost with antibiotics + PCT kit per participant (USD).
Mean cost with antibiotics + PCT kit per participant (USD)
Study Procalcitonin non-procalcitonin Between-group
absolute difference
P-value Favoured group
Deliberato 2013 977.4 1367.64 390.24 not available procalcitonin
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Analysis 3.41. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 41 Cost
reduction for antibiotic treatment.
Cost reduction for antibiotic treatment
Study Percentage of reduction P-Vaue Favoured group
Schroeder 2009 17.8% <0.01 Procalcitonin
Analysis 4.1. Comparison 4 PCT versus non-PCT (standard care or CRP: ITT analysis), Outcome 1
Mortality at longest follow-up (imputing mortality for missing participants).
Review: Effectiveness and safety of procalcitonin evaluation for reducing mortality in adults with sepsis, severe sepsis or septic shock
Comparison: 4 PCT versus non-PCT (standard care or CRP: ITT analysis)
Outcome: 1 Mortality at longest follow-up (imputing mortality for missing participants)
Study or subgroup Procalcitonin non-procalcitonin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Annane 2013 7/31 11/31 8.1 % 0.64 [ 0.28, 1.43 ]
Deliberato 2013 22/42 8/39 9.7 % 2.55 [ 1.29, 5.05 ]
Dharaniyadewi 2013 31/100 56/105 15.7 % 0.58 [ 0.41, 0.82 ]
Hochreiter 2009 15/57 14/53 10.6 % 1.00 [ 0.53, 1.86 ]
Liu 2013 6/42 5/40 5.3 % 1.14 [ 0.38, 3.45 ]
Nobre 2008 14/39 10/40 9.7 % 1.44 [ 0.73, 2.84 ]
Oliveira 2013 22/50 23/47 14.1 % 0.90 [ 0.59, 1.38 ]
Schroeder 2009 3/14 3/13 3.6 % 0.93 [ 0.23, 3.81 ]
Shehabi 2014 34/200 28/200 13.5 % 1.21 [ 0.77, 1.92 ]
Svoboda 2007 10/38 13/34 9.7 % 0.69 [ 0.35, 1.36 ]
Total (95% CI) 613 602 100.0 % 0.98 [ 0.73, 1.32 ]
Total events: 164 (Procalcitonin), 171 (non-procalcitonin)
Heterogeneity: Tau2 = 0.12; Chi2 = 20.40, df = 9 (P = 0.02); I2 =56%
Test for overall effect: Z = 0.11 (P = 0.91)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours procalcitonin Favours non-procalcitonin
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A P P E N D I C E S
Appendix 1. CENTRAL, the Cochrane Library search strategy
#1 procalcitonin or (calcitonin near (precursor* or polyprotein* or polypeptide)) or ((CGRP* or CALC*) near protein) or (alpha
protein near human)
#2 MeSH descriptor: [Sepsis] explode all trees
#3 MeSH descriptor: [Septicemia] explode all trees
#4 MeSH descriptor: [Shock, Septic] explode all trees
#5 (sepsis or septic* or blood?stream infection* or (shock adj3 (endotoxic or toxic)))
#6 #2 or #3 or #4 or #5
#7 #1 and #6
Appendix 2. MEDLINE (PubMed) search strategy
#1 (“procalcitonin” [Supplementary Concept]) OR (calcitonin precursor polyprotein) OR (CGRP1 protein, mouse) OR (CALCA
protein, human) OR (calcitonin/calcitonin-related polypeptide, alpha protein, human) OR (CGRP1 protein, human) OR (CALC1
protein, human)
#2 ((Sepsis) OR (Septicemia) OR (Blood stream infection) OR (Septic shock) OR (Endotoxic Shock) OR (Toxic Shock) OR (Severe
sepsis))
#3 ((randomized controlled trial [pt]) OR (controlled clinical trial [pt]) OR (randomized [tiab]) OR (placebo [tiab]) OR (drug therapy
[sh]) OR (randomly [tiab]) OR (trial [tiab]) OR (groups [tiab])) AND (humans [mh])
#4 #1 and #2 and #3
Appendix 3. Embase (Ovid SP) search strategy
1. procalcitonin/ or (calcitonin adj3 (precursor* or polyprotein* or polypeptide)).ti,ab. or ((CGRP* or CALC*) adj3 protein).ti,ab. or
(alpha protein adj3 human).ti,ab.
2. sepsis/ or septicemia/ or bloodstream infection/ or septic shock/ or (sepsis or septic* or blood stream infection* or (shock adj3
(endotoxic or toxic))).ti,ab.
3. (randomized-controlled-trial/ or randomization/ or controlled-study/ or multicenter-study/ or phase-3-clinical-trial/ or phase-4-
clinical-trial/ or double-blind-procedure/ or single-blind-procedure/ or (random* or cross?over* ormulticenter* or factorial* or placebo*
or volunteer*).mp. or ((singl* or doubl* or trebl* or tripl*) adj3 (blind* or mask*)).ti,ab. or (latin adj square).mp.) not (animals not
(humans and animals)).sh.
4. 1 and 2 and 3
Appendix 4. CINAHL (EBSCOhost) search strategy
S1 procalcitonin or (calcitonin N5 (precursor* or polyprotein* or polypeptide)) or ((CGRP* or CALC*) N5 protein) or (alpha protein
N3 human)
S2 ( (MH “Sepsis+”) OR (MH “Shock, Septic+”) ) OR AB ( (sepsis or septic* or blood stream infection* or (shock N3 (endotoxic or
toxic))) )
S3 random* or ((clinical or controlled) N3 trial*) or placebo* or multicenter* or prospective or ((blind* or mask*) N5 (single or double
or triple or treble))
S4 S1 and S2 and S3
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Appendix 5. LILACS (BIREME) search strategy
(calcitonin$ and (precursor$ or polyprotein$ or polypeptide)) or procalcitonin
Appendix 6. Data extraction form
Extraction sheet
Effectiveness and safety of procalcitonin evaluation for reducing mortality in adult patients with sepsis, severe sepsis and septic
shock
Study ID:
Date of study (year):
Review ID:
Reviewer:
Author (last name):
Locale of study:
I - ACTION
II - PARTICIPANTS
Participants
a. N:
b. Age:
c. Diagnosis (sepsis, severe sepsis, septic shock)
d. Baseline disease:
f. Gender:
g. Setting:
III - INTERVENTIONS
Intervention group (procalcitonin evaluation)
Control group (other biomarkers or no biomarker)
IV - OUTCOMES
(final or change from baseline values)
Primary outcomes
1. Mortality (at different time points)
• Intervention group (procalcitonin evaluation)
n:
N:
Mean:
Standard deviation:
Other statistics (e.g. median, odds ratio)
• Control group (other biomarkers or no biomarker)
n:
N:
Mean:
Standard deviation :
Other statistics (e.g. median, odds ratio)
Secondary outcomes
2. Hospital length of stay
• Intervention group (procalcitonin evaluation)
n:
N:
Mean:
Standard deviation:
Other statistics (e.g. median, odds ratio)
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• Control group (other biomarkers or no biomarker)
n:
N:
Mean:
Standard deviation:
Other statistics (e.g. median, odds ratio)
3. Intensive care unit (ICU) length of stay
• Intervention group (procalcitonin evaluation)
n:
N:
Mean:
Standard deviation:
Other statistics (e.g. median, odds ratio)
• Control group (other biomarkers or no biomarker)
n:
N:
Mean:
Standard deviation:
Other statistics (e.g. median, odds ratio)
4. Clinical severity
• Intervention group (procalcitonin evaluation)
n:
N:
Mean:
Standard deviation:
Other statistics (e.g. median, odds ratio)
• Control group (other biomarkers or no biomarker)
n:
N:
Mean:
Standard deviation:
Other statistics (e.g. median, odds ratio)
5. New infection/Reinfection
• Intervention group (procalcitonin evaluation)
n:
N:
Mean:
Standard deviation:
Other statistics (e.g. median, odds ratio)
• Control group (other biomarkers or no biomarker)
n:
N:
Mean:
Standard deviation:
Other statistics (e.g. median, odds ratio)
6. Use of antimicrobial agents
• Intervention group (procalcitonin evaluation)
n:
N:
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Mean:
Standard deviation:
Other statistics (e.g. median, odds ratio)
• Control group (other biomarkers or no biomarker)
n:
N:
Mean:
Standard deviation:
Other statistics (e.g. median, odds ratio)
V - METHODOLOGICAL QUALITY OF STUDY
Please mark the appropriate item and describe the reason.
1. Was the allocation sequence adequately generated? (please provide an explanation)
• ·’Low risk of bias’ when the authors of primary studies report methods to prevent bias.
• ’Unclear risk of bias’ when the risk of bias is uncertain.
• ’High risk of bias’ when the authors of primary studies clearly have not prevented the risk of bias.
2. Was allocation adequately concealed? (please provide an explanation)
• ’Low risk of bias’ when the authors of primary studies report methods to prevent bias.
• ’Unclear risk of bias’ when the risk of bias is uncertain.
• ’High risk of bias’ when the authors of primary studies clearly have not prevented the risk of bias.
3. Was knowledge of the allocated intervention adequately prevented during the study? (please provide an explanation)
• ’Low risk of bias’ when the authors of primary studies report methods to prevent bias.
• ’Unclear risk of bias’ when the risk of bias is uncertain.
• ’High risk of bias’ when the authors of primary studies clearly have not prevented the risk of bias.
4. Were incomplete outcome data adequately addressed? (please provide an explanation)
• ’Low risk of bias’ when the authors of primary studies report methods to prevent bias.
• ’Unclear risk of bias’ when the risk of bias is uncertain.
• ’High risk of bias’ when the authors of primary studies clearly have not prevented the risk of bias.
5. Are reports of the study free of the suggestion of selective outcome reporting? (please provide an explanation)
• ’Low risk of bias’ when the authors of primary studies report methods to prevent bias.
• ’Unclear risk of bias’ when the risk of bias is uncertain.
• ’High risk of bias’ when the authors of primary studies clearly have not prevented the risk of bias.
6. Was the study apparently free of other problems that could put it at high risk of bias? (please provide an explanation)
• ’Low risk of bias’ when the authors of primary studies report methods to prevent bias.
• ’Unclear risk of bias’ when the risk of bias is uncertain.
• ’High risk of bias’ when the authors of primary studies clearly have not prevented the risk of bias.
VI - Observation (including non-published data)
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S O U R C E S O F S U P P O R T
Internal sources
• No source of support, Other.
Own sources
External sources
• No source of support, Other.
Own sources
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
1. We selected studies and extracted data in an unblinded and dependent fashion (not independently, as previously stated in the
protocol) (Silva 2014).
2. Primary outcomes: We included mortality at longest follow-up as an additional primary outcome because absence of evidence on
mortality often results from insufficient power, as well as from clinical and methodological heterogeneity associated with primary
studies, although the latter was not the specific case for this systematic review.
3. We performed a post hoc sensitivity analysis to test the estimate of effect of the intervention by removing a study that made a
singular comparison: procalcitonin versus C-reactive protein.
4. We changed the “Synthesis of the quality of the body of evidence” section from:
◦ “We will use the principles of the GRADE system (Guyatt 2008) to assess the quality of the body of evidence associated
with mortality, hospital and intensive care unit length of stay, clinical severity, new infection/reinfection and use of antimicrobial
agents. We will also construct a ’Summary of findings’ (SoF) table using the GRADE software. The GRADE approach appraises the
quality of a body of evidence based on the extent to which one can be confident that an estimate of effect or association reflects the
item being assessed. The quality of a body of evidence reflects within-study risk of bias (methodological quality), directness of
evidence, heterogeneity of data, precision of effect estimates and risk of publication bias” to:
◦ “We used the principles of the GRADE approach (Guyatt 2008) to assess the quality of the body of evidence for our
primary outcomes of mortality at 28 days, mortality at ICU discharge, mortality at hospital discharge and time receiving
antimicrobial therapy. We imported effect estimates from RevMan 5.3 to GRADE profiler (GRADEpro 2014) to create Summary of
findings for the main comparison. This table provides outcome-specific information concerning the overall quality of evidence from
studies included in the comparison, the magnitude of effect of interventions examined and the sum of available data on outcomes
that we considered. The GRADE approach appraises the quality of a body of evidence according to the extent to which one can be
confident that an estimate of effect or association reflects the item assessed. The quality of a body of evidence is based on different
items, which reflect within-study risk of bias (methodological quality), directness of evidence, heterogeneity of data, precision of effect
estimates and risk of publication bias. Thus, we considered each of these items as having ’no limitation’, ’serious limitation’ or ’very
serious limitation’ (by downgrading them respectively for one or two levels), resulting in one of the following four overall qualities of
evidence for each outcome: ’high’, ’moderate’, ’low’ or ’very low’ quality.”
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N O T E S
Brenda NG Andriolo was previously known as Brenda NG Silva.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anti-Bacterial Agents [therapeutic use]; Biomarkers [blood]; Calcitonin [∗blood]; Intensive Care Units; Patient Discharge; Randomized
Controlled Trials as Topic; Sepsis [∗blood; drug therapy; ∗mortality]; Shock, Septic [blood; drug therapy; mortality]; Time Factors
MeSH check words
Adult; Humans
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